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Chapter 1 
GENERAL INTRODUCTION 

1 General introduction 
Psoriasis is one of the most common skin diseases, affecting about 2% of the world 
population. In the first descriptions of the disease by Hippocrates (460-377 ВС) and 
Celsius (25 BC-45 AD) psoriasis is designated as lepra-like and impetigo, respectively. 
Galen (133-200 ВС) introduced the term psoriasis ( 'psora^ itch; 'psoriasis^ scabious), 
but it still remained connected with lepra till the nineteenth century. This had an 
important social impact especially in the Middle Ages [1]. Psoriatic patients were 
isolated from the community as they were supposed to be 'infectious' [2,3]. 
Nowadays we can recognize psoriasis clinically based on the description of Willan 
[4], but the underlying defect is still unknown. After many years of research it is clear 
that the pathogenesis of psoriasis is rather complex. In an attempt to find the primary 
event and to elucidate the pathogenesis it seems worthwhile to study all aspects during 
the induction of the psoriatic lesion. This may also unmask target-structures for new 
anti-psoriatic drugs. 
In this thesis the changes in epidermal growth will be highlighted, since epidermal 
proliferation is an important feature of the disease and all anti-psoriatic therapies 
inhibit epidermal proliferation. 
1.1 CLINICAL ASPECTS 
The clinical aspects of a psoriatic lesion usually are sufficient for a reliable diagnosis 
[5]. Psoriasis is characterized by sharply demarcated, dry erythematous plaques, covered 
with silvery scales (figure 1.). Scratching-off these scales leaves a non-transparent mark 
resembling tallow-wax. After complete removal of a scale small bleeding points are 
seen: the Auspitz sign. This sign is diagnostic for psoriasis. In addition to these clinical 
features pustules are seen in two subtypes, sc. psoriasis pustulosa: type von Zumbusch 
(figure 2) and psoriasis palmo-plantaris: type Andrews-Barber. These pustules are 
sterile and constitute the macromorphological equivalent of the micro-pustule of Kogoj, 
a histological feature of psoriasis vulgaris. 
The predilection sites for psoriasis are the elbows, knees and scalp, but lesions in 
the anal cleft and other large body folds are common as well. Although these are 
typical sites, the psoriatic lesion can be found anywhere. Sometimes it covers the entire 
skin surface, resulting in erythroderma, which needs hospitalisation. 
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Figure 1. Clinical picture of chronic plaque psoriasis 
Figure 2. Psoriasis pustulosa, type Von Zumbusch 
4 
In approximately 50% of the patients the nails are involved with pitting, 
discoloration, onychodystrophy and onycholysis due to hyperkeratosis under the distal 
part of the nailplate. Arthropathy can be found in about 5% of the patients and is the 
only non-cutaneous manifestation in psoriasis. 
The onset of psoriasis can be at any age, although occurrence before puberty is 
seldom. In most patients the first symptoms are seen at the age of 20-30 years. A 
second lower peak of incidence is found between 50 and 60 years of age. 
The natural history of psoriasis is characterized by remissions and exacerbations, but 
psoriasis can be stable for years as well. The degree of instability varies per individual. 
Internal and external triggering factors such as infections, drugs, stress or skin trauma 
have an important impact on the course of the disease. Heinrich Köbner described this 
"isomorphic response" in 1878 [6]. The induction of a psoriatic lesion by a physical 
trauma demonstrates that uninvolved skin of psoriatics has the potential to turn into 
psoriasis. This phenomenon has been interpreted as a defect in the control of 
epidermal regeneration after injury [7,8]. In 25% of the psoriatic patients this phenome-
non is found, although this can vary per individual from time to time. 
Although the clinical diagnosis is generally easy, sometimes a biopsy is necessary in 
order to differentiate psoriasis from other erythematosquamous disorders. 
1.2 HISTOPATHOLOGICAL ASPECTS 
In psoriasis both dermal and epidermal compartments are involved (figure 3). The 
upperpart of the dermis shows elongated and edematous papillae with dilatated blood 
vessels and a mononuclear infiltrate. In early lesions the dermal infiltrate contains 
neutrophils as well, which penetrate the epidermis in a later stage. The epidermis shows 
acanthosis with elongation of the rete ridges, resulting in a relative increase of cells in 
the basal layer. In addition, mitoses are not restricted to the basal layer, but extend into 
the deepest rows of the suprabasal compartment. The suprapapillary part of the 
epidermis is thin with the dermal blood vessels directly underneath and this feature is 
responsible for the Auspitz sign. The stratum granulosum may be absent and micro-
pustules of Kogoj, composed of neutrophils, may be found instead. The stratum 
corneum is partly orthokeratotic, but in active lesions this compartment shows nuclea-
ted corneocytes or parakeratosis, and microabsesses of Munro, being diagnostic for 
psoriasis [9,10]. 
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Figure 3. Classical histological picture of psoriasis vulgaris 
1.3 ETIOLOGY AND PATHOGENESIS 
Although the etiology of psoriasis is unknown, the hereditary basis of this disorder is 
well-established [11]. Studies on monozygotic twins showed a concordance for psoriasis 
of 80%, whereas dizygotic twins showed a concordance of only 20% [12,13]. The trans-
mission of psoriasis in affected families has been studied by various groups. The data 
are best explained by proposing a polygenic inheritance. Indeed, HLA typing showed a 
correlation pattern which is rather heterogeneous. The following HLA types have been 
shown to correlate with psoriasis: HLA-B^, -D17, -B27, -CW6 and -DR7 [14,15]. 
In view of the polygenic inheritance of psoriasis a single metabolic defect seems 
rather unlikely. Various authors, however, have suggested a systemic enzymatic defect. 
For example, in 1989 Raynaud et al claimed a systemic defect of protein kinase A in 
psoriasis [16]. So far, however, this remarkable observation was not confirmed by other 
groups. 
Many groups suggest that epidermal proliferation present in psoriasis is a result of 
inflammation [17]. Indeed the inflammatory infiltrate appears before the epidermal 
proliferation reaches the extent as seen in the fully developed psoriatic lesion. Some 
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groups suggest that the T-lymphocytes are the most important inducer of the psoriatic 
lesion [18,19]. It has been hypothesized that the T-lymphocytes respond to non-histone 
proteins in the epidermis [20]. Other groups suggest that an increased production of 
mediators of inflammation (arachidonic acid metabolites, complement components, 
platelet activating factor, interleukins) are responsible for the induction of the psoriatic 
lesion [21,22]. Another argument in favor of this thought is the observation that in the 
distant clinically uninvolved skin the activity of phospholipase Aj (PLA^ is increased 
[23]. PLAj is the rate-limiting enzyme of arachidonic acid metabolism. The production 
of arachidonic acid metabolites is increased in the distant clinically uninvolved skin. 
On the other hand some authors suggest that epidermal proliferation is the initial 
event in the pathogenesis of psoriasis. Support for this thought is provided by the fact 
that in distant clinically uninvolved skin in the absence of any sign of inflammation, epi­
dermal growth is slightly but significantly increased [24]. Epidermal proliferation in 
psoriasis has been supposed to result from a shortening of the cell cycle time [25]. Born 
and Kalkoff [26] however, have challenged this common belief by suggesting that the 
increased thymidine labelling-index is due to an increased recruitment of cycling cells 
and a prolonged S-phase duration based on a decreased number of silvergrains per 
nucleus. The theoretical concept of increased recruitment of cycling cells as an 
explanation for psoriatic hyperproliferation was further developed by Gelfant et al [27]. 
As both inflammation and proliferation are important features of psoriasis, the 
interrelation between both processes have been the subject of recent studies (Figure 4). 
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Figure 4. A simplified scheme of common pathways for cutaneous inflammation and epidermal 
proliferation 
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In cell cultures stimulation of keratinocyte proliferation can be induced by inflammatory 
substances such as eicosanoids [28] and neutrophils [29]. Conversely, epidermal growth 
factor and standardized trauma have been shown to induce inflammation by stimulation 
of the arachidonic acid cascade [30,31]. This interrelation has been studied using in vivo 
models and summarized in a concept of common pathways for cutaneous inflammation 
and epidermal proliferation [32]. In this study the importance of these pathways for the 
etiology of psoriasis is suggested, as several metabolites are already changed in the 
clinically uninvolved skin: increased ornithine decarboxylase activity (ODC), PLA and 
arachidonic acid metabolites (AA) [21,23,33] and decreased protein kinase С (PKC) 
[34]. 
In order to study a complex system as the pathogenesis of psoriasis a simplification 
has to be made in order to provide the theoretical matrix for an in depth investigation. 
In this thesis, attention will be focused on epidermal proliferation without denying the 
pathogenic significance of inflammation. 
13.1 Proliferation 
In normal human epidermis cells in the basal layer have the potential to divide and 
replenish the suprabasal compartment, which constantly looses corneocytes at the top 
of the stratum corneum. This physiological process is well controlled and in balance. In 
case of trauma, regeneration of the epidermis takes place by an increased proliferation 
in the basal layer. Several investigators have tried to clarify the nature of these 
proliferative reserves in the basal layer and of its control [35,36]. A wide variety of 
factors are suggested to be involved in this regulatory process, such as chalones, epider­
mal growth factor, prostaglandins, cyclic nucleotides [37,38]. 
It seems likely that in psoriasis this regulation of epidermal growth is deficient, for 
clinically psoriatic lesions show an excessive scaling and thickening and histologically an 
enlargement of the basal compartment with an increased number of mitotic figures. 
Indeed, several cell kinetic parameters were reported to be abnormal by use of 
different methods. 
One of the earliest methods to assess cell proliferation was autoradiography using 
[3H]thymidine pulse-labelling [39,40]. Labelling indices (percentage of DNA synthesizing 
cells in the germinative pool) for normal epidermis were rather low, ranging between 
2,2 to 4,9 % in contrast to psoriatic epidermis with indices between 10,3 and 22,7 % 
[41]. Even the values in clinically uninvolved epidermis are slightly elevated (4,2 to 6,1 
%) compared to normal epidermis [42,43]. 
DNA measurements using flow cytometry confirm these differences in DNA 
synthesis, showing 2,7 ± 0,8 % and 9,7 ± 2,5 % DNA synthesizing cells (as percentages 
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of all epidermal viable cells) in normal and psoriatic epidermis respectively [24,44]. 
Another cell-kinetic parameter showing differences between normal and psoriatic 
epidermis is the turnover time studied by isotopie techniques. Several authors 
determined a transit time between 14 to 21 days for normal epidermis and 1,5 to 4 days 
for psoriatic epidermis [45,46]. 
These data confirm an increased proliferation in psoriasis, which was accepted by 
most groups. But there is still a controversion about the origin of this hyper-
proliferation. On one hand it can be due to a difference in cell cycle time, where 
normal epidermis takes 311 h. per cell cycle and psoriatic cells only about 36 h [47]. In 
this concept all germinative cells are participating in the cell cycle. Evidence for this 
concept is found in experiments with continuous labelling with [3H]thymidine, showing 
labelling of 60 to 85 % of the epidermal cells of mice and swine within 12 days [48,49]. 
On the other hand the explanation for psoriatic hyperproliferation can be found in 
an increased growth fraction rather than a shortening in cell cycle time [26,50]. It is 
believed that of all germinative cells only a part is actively cycling. The non-cycling or 
resting cells reside in the G0-phase (see figure 5). Changes in activity of psoriasis are 
then caused by an exchange of cells between cell cycle and G0-phase [51]. Evidence for 
the existence of a G0-phase is presented by the synchronized recruitment of cells after 
trauma [36] and data derived from continuous [3H] labelling in a cancer patient; after 
two months of exposure 30% of the germinative cells were labelled and after six 
months a plateau of 60% was reached [27]. Nowadays investigations are still focused on 
this controversy, trying to find more evidence in favor of the G0-hypothesis. 
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Figure 5. (a) the cell cycle according to the G0 hypothesis; (b) changes in DNA contení per cell during 
the cell cycle [50]. 
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13.2 Differentiation 
Besides changes in the basal compartment hyperproliferative epidermis shows changes 
in maturation in terms of keratin expression. 
Keratins are a family of intermediate filament proteins consisting of 19 different 
polypeptides in human epithelia or epithelia derived tissues [52]. These keratins are a 
major cytoplasmic constituent of keratinocytes and an essential component of the 
cytoskeleton [53]. The keratins are classified based on molecular weight (between 40 
and 68 kD) and iso-electnc values (between pH 5 and 8) (table 1). 
Table 1 The catalogue numbers of the keratins according to Moll el al [59] wiih the molecular weight 
(kD) en isoelectric pH 
nr. 
M/kD) 
I.pH 
nr. 
Mr(kD) 
IpH 
1 
68 
7 8 
11 
56 
5.3 
2 
65 5 
7.8 
12 
55 
4.9 
3 
63 
75 
13 
54 
51 
4 
59 
73 
14 
50 
53 
5 
58 
7.4 
15 
50 
49 
6 
56 
7.3 
16 
48 
51 
7 
54 
6.0 
17 
46 
5.1 
8 
52.5 
6.1 
18 
45 
5.7 
9 
64 
5.4 
19 
40 
52 
10 
56.5 
5.3 
Using two dimensional gel-electrophoresis all keratins can be visualized separately 
(figure 6). The family of keratins has been subdivided in two subgroups, i.e the basic 
and acidic keratins, amongst others based on differences in iso-electnc points [54,55] In 
most of the epithelia keratins occur in a pair of an acidic and basic keratin [56,57] as a 
functional unit Because different sets of keratins are expressed in different types of 
epithelia characterization of keratins can be of particular value in histogenetic and 
histodiagnostic studies for instance of tumours. In normal epidermis the basal and 
suprabasal compartment can be recognized by means of a different keratin expression 
[58] 
Keratinocytes m the basal layer express keratin 5, 14 and a variable amount of 
keratin 15. By contrast, in the suprabasal compartment keratins 1, 2, 10 and 11 are 
found [59]. The development of monoclonal antibodies against these keratins have 
revolutionized the visualization on histological sections and changes in keratin 
expression can be investigated [58] One of the important changes is the expression of 
keratin 6 and 16 in hyperprolifcrative epidermis, such as squamous cell carcinoma, cell 
10 
cultures and regenerative epidermis [60,61,62]. Using mRNA probes it has been proven 
that keratin 16 is not a product of immature differentiation, but merely caused by an 
alternative maturation pathway [63,64]. 
As mentioned in earlier paragraphs, psoriasis is characterized by hyperproliferation 
as well. Therefore keratin 16 expression is a focal issue in this thesis. 
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Figure 6. Schematic presentation of keratins, arranged according to their appearance on two-dimensional 
gcl-elcctrophoresis. The normal human epidermis contains keratins marked as *. BSA = bovine-scrum 
albumin; A = a-aclin 
1.4 AIM OF THE THESIS 
It was the purpose of this study to elucidate the dynamics of epidermal proliferation 
and keratinization during induction and therapeutical regression of the psoriatic lesion. 
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1.5 MARKERS AND METHODS 
1.5.1 Monoclonal antibodies and immunohistochemical methods 
In order to investigate differentiation and proliferation two different techniques were 
used, sc. immunohistochemistry and flow cytometry. For immunohistochemistry frozen 
sections were incubated with monoclonal antibodies, recognizing cell populations 
associated with one of these processes and visualized with an immunoperoxidase 
staining. The advantage of this technique is that the results of the staining pattern can 
be combined and interpreted in the light of epidermal topography and classical 
histological features. The monoclonal antibodies K,8.12, RKSE60, КІ67 and BrdUrd 
were used. These markers are briefly discussed below: 
KJ8.12: this mouse monoclonal antibody has been developed by Huszar et al. It reacts 
specifically with keratin 13 and keratin 16 in the presence of nearly all human keratins 
[65]. In a two dimensional gel electrophoresis of a cytoskeletal preparation of cultured 
human epidermoid carcinoma cells (line A-431) this antibody revealed a positive 
reaction with keratin 13 as well as in the region of keratin 15. This minor extra spot 
could be due to low amounts of keratin 15 or to a breakdown product of keratin 13. 
Immunohistochemical examination of a wide variety of human tissues showed positive 
reactions with 1^8.12 on tissues of urogenital origin, tongue and oesophagus due to 
keratin 13 expression [52,66]. Furthermore keratin 16 was detected by К,8.12 on frozen 
sections of tongue, outer sheath of hair follicles and fetal tissues, including epidermis. 
Normal human epidermis was reported to be negative in contrast to squamous cell 
carcinomas of the skin, which showed a patchy positive labelling. This reflects that 
keratin 16 is expressed in hyperproliferative epidermis [61,65]. 
RKSEóO: this mouse monoclonal antibody has been developed at the Department of 
Pathology at the University I (ospitai of Nijmegen by Dr Ramaekers and coworkers as 
an antibody against keratins. I.ater studies revealed that this antibody was monospecific 
against keratin 10, which is present in all stratified squamous epithelia [67]. 
КІ67: this mouse monoclonal antibody recognizes a human nuclear antigen present in 
proliferating cells. The existence of such antigens was indicated by autoantibodies found 
in degenerative diseases [68,69]. In 1983 Gerdes et al developed this antibody. 
Characterization revealed that it is specifically directed against proliferating cells and 
not against resting cells [70]. After stimulation resting cells could be transformed into 
cycling cells and express the antigen for КІ67. However, during the transformation from 
G 0 to G, (phase G,T, G,a and G,b) the cells were КІ67 negative (figure 7), whereas G,-
12 
cells after mitosis remained Ki67 positive [71]. All these studies were carried out on 
lymphocytes. Later studies provide accumulating evidence that КІ67 is useful for cell 
kinetic studies on epidermal cells as well [72]. 
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Figure 7. Occurrence of proliferation associated nuclear antigen recognized by monoclonal antibody KJ67 
in stimulated lymphocytes [71]. 
BrdUrd: Bromodeoxyuridine is a thymidine analogue, which can be incorporated into 
newly synthesized DNA. Immunohistochemically, BrdUrd can be visualized by 
monoclonal antibody anti-BrdUrd. For the use on epidermal cells specific protocols 
were developed to optimize fixation, DNA denaturation and protein digestion [73]. It is 
a well established alternative for [3H]thymidine and autoradiography in cell kinetic 
studies [74,75,76]. As the procedure is less time consuming, there is no need for 
radioactive tracers and the incorporation of BrdUrd can be visualized on the 
histological section itself. 
Binding with the antibodies K,8.12 and RKSE60 can be analysed by use of immuno-
histochemistry or flow cytometry. The latter approach permits simultaneous 
measurements of various cell kinetic parameters. So far no established method for 
double labelling with monoclonal antibodies КІ67 or anti-BrdUrd have been developed 
for flow cytometry. Fortunately additional cell kinetic parameters could easily be 
obtained by measurement of DNA content per cell using the fluorescent substance 
propidium iodide. A description of this technique will be given in the next paragraph. 
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1.5.2 Principles of flow cytometry and DNA measurements 
Flow cytometry has several advantages over immunohistochemistry. First, this technique 
is less time-consuming and allows to measure 5.000 to 10.000 cells within one minute 
Second, several parameters per cell can be measured simultaneously, Third, cell 
characteristics can be quantified, allowing statistical analysis. A limitation, however, is 
the loss of the topographical context of the cells [77]. 
In general, flow cytometry is used to measure optical signals, sent out by individual 
cells which are focused in a laser light beam for excitation. In figure 8 a diagram of a 
flow cytometer is given. In this thesis the flow cytometer was used to measure 
fluorescence bound to cells, dependent on their characteristics m terms of keratins and 
DNA content. Preliminary to the measurements cells are incubated with either Kß.12 
or RKSE60 and labelled with a second antibody conjugated with a green fluorescein 
isothiocyanate (GAM-FITC). Simultaneously these cells are stained with propidium 
iodide (PI), which binds quantitatively to DNA and is recognized by a red fluorescence 
[78]. During the measurements cells are excitated with an Argon laser tuned on 488 
nm. and the emissions are measured on 530 nm (GAM-FITC) and > 630 nm (PI) The 
intensity of emission light correlates with the amount of bound fluorescence Via a 
photomultiplier these optical signals are transformed into electrical pulses and stored in 
a PDP 11/45 computer for further analysis. 
For each cell, information about intensity of both red and green fluorescence can be 
stored as well as the extent of light scattering, indicating size and shape of the cell. The 
latter information can be used to discriminate cells which are damaged and lost their 
cytoplasm. These 'nude' nuclei are essentially negative for monoclonal antibodies as 
Ks8 12 and RKSE60 for these are cytoplasmatic labels. Therefore, these possibly false-
negative cells are excluded for further analysis. 
Simultaneously with the keratin pattern using RKSE60 or 1^8.12 the DNA content 
of a cell can be measured. Figure 9 shows a typical DNA-histogram of a normal 
epidermal cell suspension. The large peak represents diploid cells, such as differen-
tiated cells or cells in GÌ or GO phase. The small peak depicts cells with a double 
amount of DNA c.q. tetraploid cells as found in the G2 phase and M-phase Between 
those peaks DNA synthesizing cells are found: cells in S-phase [79]. To discriminate a 
lump of two diploid cells from tetraploid cells the ratio between the peak of emission 
(peak) and the overall emission (area) is used. 
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Figure 8. Schematic representation of flow cytometer equipped with three photomultipliers: the green 
fluorescence of the cells labelled with monoclonal antibody and GAM-FITC, the red fluorescence of 
DNA-conlcnt labelled with PI and the right angle scatter. 
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Figure 9. Schematic representation of a DNA histogram of normal human epidermis. 
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1.6 IN VIVO MODELS 
In general, studies on epidermal growth in psoriasis have been carried out by means of 
an in vivo approach. Various in vivo models permit an experimentally reproducible 
investigation of the events between symptomless and clinically involved skin and vice 
versa. 
Within the Unit for Experimental Dermatology several in vivo models have proven 
to be helpful to unravel the interplay between biological events during the transition 
from symptomless to the clinically involved state. For studies on the regression of the 
lesion, changes induced by various classical and experimental therapies can be studied 
in shave biopsies. 
1.6.1 Margin zone of spreading psoriatic lesions 
The psoriatic lesions appear as pinpoint papules which spread by coalescence. Psoriatic 
lesions can be stationary for many months or years. In unstable phases of the disease, 
lesions may spread by centrifugal expansion. The rim of lesions in a phase of growth is 
more erythematous and pinpoint papules surround the plaques. 
The margin zone provides an adequate model for sequential studies on the order of 
events at the cellular and subcellular level from clinically uninvolved to the lesionai 
state [82,83,84]. Although at the macromorphological level the lesions are sharply 
demarcated, the histological and biochemical events show a more gradual transition. 
In the earliest phase of the lesion, the histologic appearance is aspecifíc. A mild 
inflammatory infiltrate predominantly localized in the perivascular regions is observed. 
So far, no agreement has been reached on the question which cell type invades first the 
skin: the polymorphonuclear leukocytes [80], the T-lymphocytes [17] or the mast cell 
[81]. Acanthosis is observed after these initial changes. Acanthosis in psoriasis adopts a 
typical architecture with elongated rete ridges and a thinning of the suprapapillary 
plate. 
1.6.2 Response to standardized injury 
Sellotape stripping is a reproducible and relatively non-invasive surface trauma. This 
standardized trauma has been advocated as a model to study the dynamics of recovery 
of skin barrier functions [86,88], epidermal proliferation [36,89] and inflammation 
[87,90]. A similarity between the psoriatic lesion and epidermal proliferation induced by 
tape stripping is the increased recruitment of cycling cells from the resting G0 
population [36,50]. 
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This method, originally described by Pinkus [85], results in a complete removal of 
the stratum corneum adhesive tape is applied repeatedly to the skin surface until a 
glistening appearance can be observed At that moment the application of the tape is 
experienced by the patient as tender. No more cells will stick to the adhesive tape as 
the removal of the stratum corneum results in a wet surface. Microscopical examination 
of the adhesive tape at this moment will not show corneocytes any more. In this thesis 
changes in keratmization during the induction of hyperprohferation after sellotape 
stripping were studied in order to elucidate the relation between proliferation and 
differentiation. 
1.63 Therapeutical regression of the lesion 
Various treatments are available for the routine dermatológica! practice For a more 
detailed account the reader is referred to monographs on psoriasis [91]. The choice of a 
treatment modality depends on the degree of involvement. Patients with minimal to 
moderate expression of the disease are treated on an out-patient regimen with 
dithranol, tar or topical corticosteroids A more extensive involvement justifies 
treatment with ultraviolet B-light or photochemotherapy In case of severe psoriasis, 
resistant to these treatments, either the patient is admitted to the in-patient department 
for a course with dithranol, or a systemic treatment with methotrexate or retinoidb is 
prescribed In general, the cumulative toxicity potential of anti-psonatic therapies limits 
the continuous use of one simple therapy and necessitates courses of different therapies 
throughout a patients life. 
The working mechanisms of classical antipsonatic therapies are largely unknown 
Investigation of multiple parameters in biopsies taken before and during treatment with 
classical and experimental treatments is an important in vivo approach to learn more 
about the underlying mechanisms [92] Further these parameters represent a 
histological assessment which might extend the discrimination level of the naked eye 
and provide additional information about the clinical resolution of the psoriatic lesion 
1.7 APPLICATIONS AND QUESTIONS 
At different phases of the in vivo models described in section 1 6, biopsies were taken 
and the dynamics of epidermal proliferation and keratmization were assessed using the 
parameters described in section 1.5. A classical therapy (dithranol) was optimized for 
out-patient use and an experimental treatment was evaluated by use of clinical parame-
ters. In addition the therapies were monitored with the parameters (section 1 5) of cell 
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biological technology. 
The following questions were addressed: 
(i) Are the existing monoclonal antibodies useful tools to confirm and clarify 
changes in both proliferation and keratinization as found in psoriasis? (chapter 2 
and 3) 
(11) Is psoriatic hyperproliferation characterized by a change of the cell cycle time or 
by an increased recruitment of cycling cells? To what extent are these changes 
specific for psoriasis? (chapter 2) 
(in) What is the relation between epidermal hyperproliferation and keratinization as 
found in in vivo models? (chapter 4) 
(iv) Can the classical dithranol treatment be improved, and is the experimental treat­
ment with vitamin D3 effective in psoriasis? (chapter 5 and 6) 
(v) To what extent is the clinical response to a classical treatment reflected 
quantitatively in changes of proliferation and differentiation markers and are 
these parameters useful in monitoring a new treatment? (chapters 5 and 6) 
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Chapter 2 
HYPERPROLIFERATION 

2 A sequential double immunoenzymic staining procedure 
to obtain cell kinetic information in normal and hyper-
proliferative epidermis 
P.E.J, van Erp, S. de Mare, J.J. Rijzewijk, P.C.M. van de Kerkhof, F.W. Bauer. 
Histochemical Journal 1989; 21:343-347 
This work was presented at the Ιβ"1 annual meeting of the E.S.D.R., Munich, 
June 19*· - 22*, 1988 
A sequential double immunoenzymatic staining procedure was developed using the 
monoclonal antibody anti-BrdUrd and Ki67 in order to determine whether hyperproli­
ferative skin disorders, such as psoriasis, are characterized by an increased growth 
fraction rather than a much shorter eel) cycle time of all germinative cells. КІ67 binds lo 
a proliferation-associated nuclear antigen in a variety of human cell types, and anti-
BrdUrd can be used to identify DNA-synthesizing cells. Although in hyperproliferative 
epidermis the absolute numbers of BrdUrd-positive cells as well as Ki67-positive cells 
were grossly increased, the ratio of these values was not changed compared to the ratio 
found in the epidermis of the clinically uninvolved skin of psoriatic patients and in 
normal epidermis. This suggests an increased growth fraction in hyperproliferative 
epidermis. 
Our data show that immunohistochemical double-staining techniques can be a 
valuable tool in the study of cell cycle kinetics in epithelial tissues. 
Introduction 
Human epidermis is a renewing cell population in which cell production equals the 
physiological loss; following a trauma, the production rate increases sharply and 
remains high until the injury is repaired. How this process is controlled has not been 
completely understood. One possible way of controlling the production of keratinocytes 
can be the recruitment of resting cells from a G 0 population. Boezeman et al [1], using 
a mathematical analysis of DNA distributions at different times following injury, have 
shown that G 0 population does in fact exist in human epidermis in vivo; their data 
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made it clear that under normal circumstances only a minority of cells are actively 
cycling. The monoclonal antibody КІ67 has been shown to recognize a nuclear antigen 
in proliferating blood cells [2] and in other cells [3,4] and therefore could be used to 
detect the presence of actively cycling cells in human epidermis. Using the monoclonal 
antibody Pab601 [5] for the total germinative cell population and КІ67 for cycling cells 
on serial cryostat sections, we have shown that the actively proliferating cell pool 
(growth fraction) in normal epidermis is 5-10% of the total germinative cell population. 
Preliminary data indicated that psoriatic lesiona) skin contains significantly fewer G 0 
cells, having a growth fraction up to 80% [6]. 
The aim of this study was to develop a sequential double immunoenzymatic staining 
procedure using a monoclonal antibody against the thymidine analogue 
bromodeoxyuridine for S-phase cells [7] and КІ67 for actively cycling cells. This has 
been used to provide further independent data regarding the size of the growth fraction 
in hyperproliferative disorders such as psoriasis and atopic dermatitis. 
Methods and materials 
We selected three patients with atopic dermatitis and 15 patients with chronic plaque 
psoriasis. All patients with atopic dermatitis were treated with topical corticosteroid. 
Eight of the psoriatic patients were treated with either corticosteroids or methotrexate, 
whereas the others had received no therapy for at least one month. The seven healthy 
control subjects were paid volunteers with no sign or history of skin disease. 
Microbiopsy specimens (3 mm in diameter and about 2 mm thick) were taken 
freehand using a razor blade in conjunction with a metal guard [8]. In all patients the 
lesionai skin and in four of the untreated psoriatic patients both lesionai and distant 
clinically uninvolved skin were biopsied. 
Skin biopsies were washed in phosphate-buffered saline (PBS) and floated, dermal 
face downward, in a 5 ml glass bottle containing 2 ml Medium 199 with Hanks' salts, 25 
m M Hepes, L-glutamine (Gibco, Paisley, Scotland) and 135 /»g/ml bromodeoxyuridine 
(Serva, Heidelberg, FRG) for 1 h at 370C in air at 1 atmosphere effective pressure. The 
incubation was stopped by transferring the biopsies to a petri dish containing ice-cold 
PBS. Biopsies were embedded in Tissue-Tek II OCT compound (Miles Scientific, 
Naperville, USA) in a cryostat at -20oC. Sections of 8 ¿im were cut and fixed directly in 
acetone-ether (60/40 v/v) for 10-20 min. Fixed and air-dried sections were either kept at 
-20oC or used directly. 
The double labelling procedure as it was routinely used is given below. Dilutions for 
each antibody were optimized, and control experiments were carried out as described in 
the result section. After 3-5 min incubation in PBS containing 0.01% Tween 80, the 
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sections were incubated for 30 mm at room temperature in a moist chamber with Ki67 
(Dakopatts, Copenhagen, Denmark) diluted 1*20 in PBS, washed with PBS and 
subsequently incubated for 30 mm with a peroxidase-conjugated rabbit anti-mouse 
antibody (Dakopatts) at a dilution of 1:25 in PBS containing 5% human AB serum 
After washing with PBS the bound peroxidase was developed with the 3-amino-9-et-
hylcarbazole H 2 0 2 reaction for 20 mm The sections were rinsed in distilled water and 
hydrolysed for 10 mm in 4N HCl at room temperature in order to denaturate DNA 
partially. Binding of the monoclonal anti-BrdUrd requires regions of single-stranded 
DNA Exact denaturation conditions were established previously [9]. After two washes 
with PBS the sections were incubated for 30 mm with anti-BrdUrd (Becton & 
Dickinson, Mountain View, USA), diluted 1:10 in PBS containing 0.5% Tween 20 The 
sections were washed with TRIS-buffer (pH 9.1) and incubated for 30 mm with an 
alkaline phosphatase-conjugated rabbit anti-mouse antibody (Dakopatts) at dilution of 
1 10 in TRIS buffer containing 1% human AB serum After washing with TRIS buffer, 
the bound alkaline phosphatase was visualized with naphthol AS-MX phosphate and 
Past Blue RR as a chromogen for 10 mm Sections were finally rinsed in distilled water, 
mounted in glycerine gelatine and the number of positive cells counted per mm length 
of section. 
Results 
The cycling cell population was visualized using the monoclonal anti-(human 
proliferating cells) antibody Ki67 and a peroxidase-conjugated second antibody Ki67 
was tested in the range 1.4 to 1.50. Higher Ki67 concentrations resulted in more 
nuclear signal. However, with dilutions in the range 1.4 to 1 10 the background signal 
(in particular cytoplasmic labelling of basal cells) interfered with the nuclear staining 
Every batch of peroxidase-conjugated second antibody as well as alkaline phosphatase-
conjugated second antibody was tested for optimum concentration Although small 
variations did exist, dilutions of 1 25 and 1 10, respectively, were generally used After 
hydrolysis in 4N HCl, anti-BrdUrd antibody was added and visualized using alkaline 
phosphatase-conjugated goat anti-mouse IgG. The primary idea of hydrolysis was to 
denature DNA, but it also destroyed all the antibodies present in the cryostat section 
without interfering with the insoluble peroxidase product. Control experiments in which 
the second labelling step with anti-BrdUrd and the alkaline phosphatase conjugate were 
omitted revealed similar Ki67 results. Experiments in which we first denatured DNA, 
labelled with anti-BrdUrd, and Ki67 was used as the second monoclonal antibody, failed 
presumably due to destruction of the nuclear antigen for Ki67 
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Figure 1. Double immunoenzymatic staining of S-phase cells (blue) and cycling cells (brown) in 
normal epidermis (magnification lOOx). 
Figure 2. Double immunoenzymatic staining of S-phase cells (blue) and cycling cells (brown) in lesionai 
epidermis of an untreated psoriatic patient (magnification lOOx). 
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Both antibodies recognize antigens located in the cell nucleus. Cell nuclei binding 
anti-BrdUrd (i.e. having incorporated bromodeoxyundine) are in S-phase of the cell 
cycle. These BrdUrd-positive cells should also bind KJ67. Fig 1 shows clearly that those 
nuclei that stained blue (alkaline phosphatase) have a brown precipitate (peroxidase) 
underneath as well. A detail of psoriatic lesionai skin is shown in Fig.2. A grossly 
increased number of BrdUrd-positive nuclei, as well as Kj67-positive nuclei can be 
observed compared to normal skin (Fig.l). 
In accordance with previous findings [6], evaluation of Ki67 binding in normal 
epidermis can sometimes be difficult due to staining of the cell cytoplasm in addition to 
the nuclear binding of the monoclonal antibody. In contrast to normal skin, Ki67 
staining of cycling cells in hyperproliferative epidermis such as psoriasis gives much less 
problem regarding non-specific cytoplasmic staining. Mean values of numbers of 
BrdUrd-positive and Ki67-positive cells per mm length are given in Table 1. Increased 
numbers for BrdUrd-positive cells as well as Ki67-positive cells are found in lesionai 
epidermis of psoriasis and atopic dermatitis. The ratio of the number of S-phase cells 
and the number of cycling cells for each condition is given in Table 1 (column 4). 
Similar mean values can be observed for normal as well as hyperproliferative skin A 
scattergram of the data for individual biopsies is illustrated in Fig.3, no major 
differences in ratios of BrdUrd positive cells/Ki67 positive cells (Ng/N^) can be found 
(correlation coefficient = 0.961, ρ < 0.01). 
Tabic 1 BrdUrd-positive cells per mm section length, Ki67-positive cells per mm section length and the 
calculated LI (ratio BrdUrd-positive Ki67 positive cells) for the various groups of specimens All values 
arc means ± SEM 
Specimen 
normal epidermis 
psoriasis unmvolved 
psor. involved (treated) 
psor. involved (untreated) 
atopic dermatitis 
η 
7 
4 
8 
7 
3 
BrdUrd + 
8.6 ± 1.0 
6.3 ± 0.8 
62.1 ± 7.8 
76.1 ± 9.4 
48.8 ± 11.6 
Ki67 + 
24.7 ± 2.2 
19.7 ± 2.2 
191.2 ± 20.3 
196.9 ± 22.4 
135.3 ± 41.7 
LI 
0.349 ± 0.014 
0.322 ± 0.014 
0.324 ± 0.012 
0.395 ± 0.031 
0.374 ± 0.027 
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Because data to support the specificity of KJ67 in human epidermis are limited, 
preliminary experiments were carried out to test the suitability of the antibody for 
staining proliferating epidermal keratmocytes. Firstly, the majority of human keratmo-
cytes cultured on 3T3 feeder cells in the presence of serum express Ki67 antigen After 
48h serum starvation about 30% of the cells became Kj67-negative. Secondly, 40h after 
a standardized trauma of the skin (sellotape-stnpping of the stratum corneum) in order 
to induce hyperproliferation, an induction was observed of Ki67-positive cells in the 
lower layers of the epidermis. 
Discussion 
The results of this study suggest the existence of a population of resting (G0) cells in 
normal and hyperproliferative epidermis. In hyperproliferative epidermis, however, the 
majority of germinative cells are cycling, whereas in normal epidermis only a small 
fraction is cycling. The monoclonal antibody KJ67 used in this study to label all cells in 
S, G2, M phases and the majority of cells in G, phase, but not G0 phase and 
differentiated cells [10], stains only a small proportion of all germinative cells in normal 
skin In hyperproliferative skin disorders the number of Ki67-positive cells increases 
dramatically. 
Two methods are described in the literature for determining the number of 
keratmocytes in S-phase of the cell cycle: autoradiography and cytometry [11]. With 
autoradiography, after incorporation of a radioactive DNA precursor ([3H]thymidine or 
["CJthymidine) into DNA, cells actively synthesizing DNA can be visualized With 
cytometric methods the DNA content of individual cells can be measured using a 
quantitative DNA stain In this way, the fraction of cells in S-phase can also be 
determined. For this study, we have chosen a recently developed method using a 
monoclonal antibody to detect actively DNA synthesizing cells [7]. Bromodeoxyundine 
(BrdUrd), a pynmidine analogue of thymidine can be identified in the nucleus after its 
incorporation into DNA by means of an anti-BrdUrd monoclonal antibody This 
method gives similar results to autoradiography [12,13], but has the advantage that 
straight immunohistochemical methods can be used to quantify S-phase cell numbers 
Total numbers of Ki67-positive and BrdUrd-positive cells in hyperproliferative skin 
disorders are both grossly increased, as shown in Table 1. Absolute numbers using per 
mm length of cryostat section should be interpreted with caution because of technical 
aspects, for instance tissue orientation when sections are cut [14] and because of 
ditterences in tissue architecture when psoriatic lesionai skin and normal skin are 
compared. However, combining both Ki67 and anti-BrdUrd labelling in a sequential 
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double staining a true independent LI can be measured, according to the following 
equation-
N* 
LI = 
where N
s
 is the number of S-phase cells and N^ the number of actively cycling 
(Ki67-positive) cells. Table 1 shows the LI for normal skin, psoriatic lesionai skin, 
psoriatic umnvolved skin and lesionai skin of patients with atopic dermatitis Obviously, 
the values of LI as we calculated them are much higher than those reported in the 
literature, because we have used the cycling cell population as the reference, whereas 
others have used an estimate of the total germinative compartment [15,16] In contrast 
to these latter studies we show that LI in hyperproliferative skin is not different to that 
found in normal skm This remarkable finding is best illustrated by plotting the number 
of BrdUrd-positive cells per unit length against the number of Kj67-positive tells per 
unit length for each individual (Fig 3) 
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Figure 3 Correlation between numbers of BrdUrd positive cells and numbers of Ki67 positive cells in 
individual biopsies Open square = normal, cross = psoriasis umnvolved, triangle = atopic dermatitis, 
diamond = psoriasis lesion (untreated), point = psoriasis lesion (treated). 
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Calculation of absolute cell cycle times depends on the assumption that cells are 
randomly distributed through the various phases of the cycle. Although this assumption 
has been questioned [17], it has been used by various investigators in this field (for 
example,[ll]). It follows that: 
Ns T
s 
Ν Τ 
where T
s
 is the duration of S-phase and T^ is the cell cycle time. Having determined 
the ratio of N 9 over N^ and knowing from the literature [11] that T s is relatively 
constant for normal epidermis as well as psoriatic lesion (varying from 6.5h to 16h, 
averaging about 10h), the cell cycle time of actively dividing keratinocytes in human 
skin can be calculated to be 28h. This figure is compatible with that of 26h found by 
direct observation of keratinocytes in culture, with the value of about 25h found by 
Rijzewijk et al [18] and also with 39h using the stripped skin model [1]. 
The present study demonstrates that an immunohistochemical double staining 
technique can be an useful tool in studying cell cycle kinetics in epithelial tissues in 
general, and in epidermis in particular. Using ratios of numbers of BrdUrd-positive cells 
over numbers of Ki67-positive cells methodological and technical problems with respect 
to cell counting were omitted. The technique is reproducible and accurate despite the 
many steps that are needed; labelling with the antibodies must be sequential because of 
the denaturation step required for anti-BrdUrd binding. 
With respect to the cell kinetic results we state firstly that, although evidence is 
accumulating, in particular for blood cells and also for other cell types that КІ67 is a 
reliable marker for cycling cells, further research concerning its specificity in epidermis 
is urgently needed. The appearance of Ki67-positive and Ki67-negative cells in several 
layers in the basal region of psoriatic lesionai skin, suggests an increased germinative 
compartment, as was described by Bauer et al [11] and Van Erp et al [6] using 
monoclonal antibodies against intermediate filament-proteins. Because total epidermis 
is also much thicker, there is a relative increase of the germinative compartment from 
30% to 50% [11]. However, the absolute numbers of Ki67-positive and BrdUrd-positive 
cells have increased in psoriatic lesionai skin 8- to 10-fold (Table 1). In conclusion, 
using this sequential double immunoenzymatic staining procedure we show that there is 
no major difference between normal and hyperproliferative skin with respect to cell 
cycle time and it suggests an increased growth fraction. Differences reported in the 
literature could be the result of overestimation of the growth fraction in normal 
epidermis. We think that further research concerning increased cell proliferation and its 
significance for the pathogenesis of psoriasis and other hyperproliferative skin disorders 
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should be focused around the mechanisms involved in controlling the recruitment of 
resting (G 0 ) cells and the roles of other epidermal subpopulations (differentiated cells, 
Langerhans cells, infiltrate cells). 
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Chapter 3 
ΚΕΚΑΉΝΙΖΑΤΙΟΝ 

3 Epidermal hyperproliferation assessed by monoclonal 
antibody KJi.12 on frozen sections 
S de Mare, Ρ E J van Erp, P C M van de Kerkhof. 
Journal of Investigative Dermatology 1989, 92: 130-131 
This work was presented at the 18th annual meeting of the E S D R, Munich, June 
19th-22th, 1988 
Using the monoclonal antibody Κβ 12 directed against keratms 13 and 16, we have studied 
psoriatic and trauma-induced hyperproliferation In normal skin 40h and 64h attor 
sellotape stripping and in psoriatic lesions, a pronounced suprabasal staining by K
s
8 12 was 
observed In unstnped normal skin and in the clinically uninvolved skin of psoriatic 
pdtients some patchy staining limited to the basal layer was seen The clear distinction 
between normal and hyperprohferative skin in keratin expression as detected by K
s
8 12 
indicates that this antibody may serve as a marker for epidermal proliferation in psoriasis 
Introduction 
Keratinocytes in culture are characterized by the appearance of low molecular weight 
keratins, including a 48 kDalton keratin (keratin 16) These keratins are also expressed in 
the lesionai epidermis of psoriasis [1] Of special interest is keratin 16 First, this keratin is 
expressed exclusively in hyperproliferative skin disorders such as psoriasis and squamous 
cell carcinomas and it has been reported to be absent in normal skin [1,2] Second, the 
reduction of this particular keratin has been claimed as the most reliable marker of clinical 
resolution of the psoriatic lesion [3] 
To characterize the keratins m psoriasis, Sun and co-workers have carried out elaborate 
investigations combining immunohistochemical staining with the monoclonal antibody AE1, 
which recognizes the acidic subfamily of keratins [4], including keratin 16, and SDS 
Polyacrylamide gelelectrophoresis [1,5] These studies showed that this keratin, amongst 
3 7 
others, is expressed in the suprabasal layers of lesionai epidermis and in regenerating 
epidermis of healthy controls. 
Recently, a new monoclonal antibody reactive with keratins (Κ,8.12) has been 
characterized by Huszar et al [6]. The immunoblotting analysis showed a specific binding 
of this antibody to keratins 13 and 16. A minor extra spot in the region of keratin 15 was 
only seen in an epidermal carcinoma cell line. Neither normal nor diseased epidermis 
contain keratin 13 [6,7]. Keratin 15 is expressed by basal cells of normal human epidermis 
in minor amounts [7], therefore KJi.ll may be regarded as specific for keratin 16 in the 
suprabasal layers of the skin. In this paper we report the distribution and degree of 
expression of keratin 16 in lesionai and clinically uninvolved skin of psoriatic patients and 
in regenerating epidermis of healthy volunteers as detected by this monoclonal antibody. 
Materials and methods 
Skin sampling 
Razor-blade biopsies (5 mm diameter, 0.3 mm thickness) were taken from the normal skin 
of eight healthy volunteers and from the lesionai and clinically uninvolved skin of four 
patients with stable chronic plaque psoriasis. Further biopsies were taken from 
sellotape-stripped sites [8] on two subjects at 40 and 64 h after stripping; these times were 
selected because regeneration is initiated about 40 h after injury and is well-established at 
64 h [9]. 
Immunolmtochemical staining 
All biopsies were frozen immediately in Tissue-Tek II OCT compound (Miles Scientific, 
Naperville, U.S.A.) and sectioned at 8μΐη. After fixation with acetone-ether (60/40 v/v), the 
frozen sections were washed in phosphate-buffered saline (PBS) containing 0.01% Tween 
80. Slides were incubated for 30 min at room temperature with Κ,δ.ΙΖ (Bio-Yeda, 
Rehovot, Israel) diluted 1:40 in PBS. After three washes with PBS the slides were 
incubated for 30 min at room temperature with peroxidase-conjugated rabbit anti-mouse 
immunoglobulins (Dakopatts, Copenhagen, Denmark) diluted 1:25 in PBS containing 5% 
human AB-serum. After three further washes with PBS and a preincubation with sodium 
acetate buffer (pH 4.9), slides were finally stained in sodium acetate buffer containing 200 
mg/1 3-amino-9-ethylcarbazole solution and 350 μ]β 30% H202 (prepared freshly) for 10 min 
at room temperature in the dark. 
After two washes with demineralized water, slides were counterstained with 
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haematoxylin (Mayer) and mounted in glycerine gelatine. The slides were studied using a 
Leitz Laborlux 12 light microscope. 
Results 
K
s
8.12 staining of normal skin was patchy with a sharp demarcation between positive and 
negative areas. The percentage of cells staining varied between healthy volunteers, but was 
minimal and always restricted to deeper rete ridges of the basal layer. Figure 1 
demonstrates an example representative of all the healthy volunteers. The clinically 
uninvolved skin of psoriatic patients showed an essentially similar pattern to that observed 
in healthy volunteers. 
V ^Лі 
Figure 1. К,8.12 staining of normal skin. (»Sin 
us/ : %/ • ν* --¡Μ*· 
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Figure 2. К,8.12 staining of psoriatic lesion. (xl90). 
Figure 3. Κ,β.Π staining of normal skin 40 h after sellotape stripping. (x80). 
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In contrast, the lesionai skin of all patients showed a positive K,8.12 staining of the 
suprabasal layers, which was more pronounced and uniformly distributed. In figure 2 these 
characteristics can be seen. This difference between lesionai skin (four patients) and 
clinically uninvolved skin (4 patients and 8 healthy controls) was clearly evident. Statistical 
analysis (two-tailed Wilcoxon ranking test) revealed a highly significant difference 
(P<0.01). 
K
s
8.12 staining in tape stripped skin of normal volunteers showed a pattern resembling 
the distribution in lesionai skin of psoriatic patients. In all biopsies, 40 h after 
tape-stripping Κ,8.12 binding was in the suprabasal layers but was less uniformly 
distributed and less marked than that seen in the psoriatic lesion (Fig 3). After 64 h the 
suprabasal staining showed within the same section a wide variation in intensity. In 
addition, basal staining was seen in all biopsies of stripped skin, showing the same patchy 
distribution as their unstriped equivalents. No sharp demarcation was seen between 
suprabasal staining and the relatively inconspicuous basal staining. The frontier of K
s
8.12 
staining at 40 h after stripping was located at the top of the stratum spinosum and by 64 h 
had advanced to the stratum corneum conjunctum. 
Discussion 
In the psoriatic lesion a subfamily of acidic keratins, confined to the basal layer of normal 
skin [5], is expressed in the suprabasal cell layers. One of the most important of these 
keratins is keratin 16. In the present study we visualized this characteristic change in the 
expression of keratin 16 in hyperproliferative epidermis. 
This investigation demonstrates that the immunohistochemical use of K
s
8.12 permits a 
reliable distinction between the hyperproliferative epidermis of the psoriatic lesion or 
regenerating skin and the epidermis of normal skin. In the psoriatic lesion keratin 16 is 
expressed in the whole suprabasal compartment except the stratum corneum. Because 
cycling cells do not occur in the upper part of the stratum spinosum [10], the expression of 
keratin 16 seems more likely a consequence of hyperproliferation than a cause. 
In normal skin no K
s
8.]2 staining has been observed in the suprabasal cell layers. A 
minor and variable staining was seen in the basal layer of these sections. Although keratin 
16 is supposed to occur exclusively in the suprabasal layers [11] of hyperproliferative 
epidermis and to be absent in normal skin [1,2], Kim et al reported that this keratin is 
expressed in basal cells of cultured human epidermis [12]. If we assume that this patchy 
staining is due to keratin 16 expression in the deeper rete ridges, then this observation 
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supports the contention of Lavker and Sun that the basal cells in these locations are 
hyperproliferative compared to basal cells elsewhere [13]. Perhaps a less controversial 
explanation for the basal staining in the present study is cross-reactivity with keratin 15 
[2,6,7]. 
The heterogeneity of the staining intensity in the biopsies 40 and 64 h after stripping is 
a remarkable finding. This pattern suggests a variation in expression of keratin 16 during 
the process of epidermal recovery following injury. It has been shown that a synchronized 
cohort of cells enter the cycle at about 40 h after stripping, and it is possible that changes 
in keratin 16 expression are related to the subsequent progress of this cohort through the 
cycle. Further studies are necessary to test this hypothesis. 
The simplicity of the method makes it very attractive for studies on proliferation in 
skin The striking difference between normal and lesionai skin of psoriasis in terms of 
KjS 12 staining makes it a very interesting parameter for studies on this disease 
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Chapter 4 
IN VIVO MODELS 

4.1 Flow cytometric quantification of human epidermal cells 
expressing keratin 16 in vivo after standardized trauma 
S. de Mare, P.E.J, van Erp, F.C.S. Ramaekers, P.C.M. van de Kerkhof. 
Archives of Dermatological Research 1990; 282:126-130 
This work was presented at the annual meeting of the A.D.F., Cologne, 
November 4,h-6,h,1988 
The intermediate filament protein keratin 16 is expressed in hyperproliferative 
epidermis. The present study aims to clarify the relationship between the expression of 
this keratin type, hyperproliferation (percentage of cells in SG2M phases), and 
keratinization (keratin 10 expression). 
These three parameters were quantified in biopsies taken at different time intervals 
following sellotape stripping - this being a dynamic in vivo model for the induction of 
hyperproliferation. From these biopsy specimens cell suspensions were prepared, 
labelled with antibodies K,8.12 (specially directed against keratin 16) and RKSE60 
(directed against keratin 10) and analyzed using flow cytometry. Percentages of cells in 
SG2M phases were assessed by measuring the relative DNA content after propidium 
iodide staining. 
Keratin 16 expression in the suprabasal layer anticipated epidermal proliferation, 
suggesting a role of the suprabasal compartment in the induction of epidermal growth. 
Keratin 10 expression decreased about one day after the onset of keratin 16 expression, 
indicating that these processes do not depend directly upon each other. 
Introduction 
Epidermal hyperproliferation is one of the most striking features of the psoriatic lesion. 
In addition to the abnormalities in the basal cell layer associated with 
hyperproliferation, the psoriatic suprabasal compartment also shows biochemical 
changes inherent in this process. Apart from the keratins normally expressed in the 
differentiated cell pool (keratins 1, 2, 10 and 11), the suprabasal cells in the psoriatic 
lesion are characterized by a marked expression of keratins 6 and 16 [1,2,3]. Keratin 16 
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is not specific for psoriasis, as it is found in other hyperproliferative situations such as 
keratinocyte culture [2], squamous cell carcinoma [4], and regenerating epidermis 
[1,5,6]. In contrast, studies using immunoblotting and gel electrophoresis revealed that 
keratinocytes of normal skin do not express this keratin type [1,2,3]. In view of the fact 
that keratin 16 is firmly linked to hyperproliferation, this keratintype is of interest for 
studies on epidermal growth. 
In the present investigation the dynamics of keratin 16 expression was studied 
during the induction of epidermal hyperproliferation. The sellotape stripping method as 
described by Pinkus [7] was used as a model to induce epidermal hyperproliferation in 
vivo. In particular the appearance of keratin 16 and the degree of its expression were 
studied at different time intervals by flow cytometric quantification using the 
monoclonal antibody 1^8.12. It has been shown that this monoclonal antibody reacts 
with both keratins 13 and 16 [8]. However it can be used for the specific detection of 
keratin 16 since epidermis does not express keratin 13 [9]. 
Boezeman et al. [10] have recently shown a significant increase of DNA synthesis in 
biopsy specimens of normal skin 40 h after sellotape stripping; it was demonstrated that 
at that time a synchronized cohort of cells goes through S phase. After this interval 
keratin 16 expression is already prominent in the suprabasal layers of stripped skin 
[1,5]. The relationship between keratin 16 expression and DNA synthesis during 
regeneration is a central question in the present investigation. Simultaneously with the 
measurements of keratin 16 expression the percentages of cells in SG2M phases were 
determined using propidium-iodide as a quantitative marker for DNA [11]. 
In contrast to keratin 16, which is absent in normal skin and appears in 
hyperproliferative conditions, keratin 10 is related to a normal keratinization process 
[3,12]. Stoler et al. emphasise that the induction of hyperproliferation related keratins is 
associated with the down-regulation of the terminal differentiation-specific keratins [13]. 
The aim of the present investigation is to assess the sequence of changes in the 
expression of both kinds of keratins and the relationship in time between those 
changes. 
Materials and methods 
Subjects and skin sampling 
Eight healthy volunteers (5 men and 3 women, aged between 24-27 years) participated 
in the study. At ten sites on their backs, sellotape stripping was performed as described 
b> Pinkus [7]. In brief, adhesive tape was applied repeatedly to these sites (2 cm2). 
Removal of the stratum corneum was considered to be complete when the whole area 
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appeared to be glistening; this usually required 15-25 applications of the tape. Biopsy 
specimens were taken 4 h, 8 h, 16 h, 24 h, 32 h, 40 h, 48 h, 56 h, 64 h and 72 h after 
stripping. As individual reference one extra biopsy was taken from an unstriped site. 
Biopsy specimens were taken with a razor blade in conjunction with a metal guard, the 
average diameter and thickness being 5 mm and 0.3 mm, respectively. 
Analytical procedures 
Cell suspensions were prepared using a trypsinization procedure as described by Bauer 
et al. [11] in order to dissociate biopsy specimens into single cells. In brief, the biopsy 
material was washed in phosphate buffered saline (PBS) and floated with the dermal 
site downward on a solution containing 1% trypsin (DIFCO, Detroit, Mich.) and 0.3% 
dithioerythritol (Sigma, St Louis, Mo.) in PBS for 20 min at ЗТ'С. Subsequently, the 
biopsy material was fixed in 500 μ\ cold ethanol (70% v/v), dissociated by sonification 
(Sonifier B-12, Branson Sonic Power Company, Danbury, Coun.) for 5 s at 70 W and 
an additional amount of ethanol added to a total volume of 1500 μί. Since dermis and 
stratum corneum remained intact, the cell suspension contained only epidermal cells. 
The cell suspensions were stored at -20oC until use. 
An aliquot of 200 μί of this cell suspension was centrifuged and rehydrated in PBS 
containing 1% normal goat serum (NGS; Sera-lab, Sussex, England). Cells were 
incubated with monoclonal antibody K,8.12 (Bio-Yeda, Rehovot, Israel; diluted 1:30 in 
PBS/NGS) or monoclonal antibody RKSE60 (diluted 1:10 in PBS/NGS) [15,16] for 30 
min at room temperature (RT). After two washes with PBS/NGS and centrifugation at 
1000 χ g for 5 min the second antibody goat-anti-mouse IgG and IgM conjugated with 
fluorescein isothiocynate (GAM-FITC; Tago, Burlingame, Calif., diluted 1:25 in 
PBS/NGS) was applied to the cells for 30 min at RT. Thereafter cells were again 
washed twice. Finally, the sediment was resuspended with 200 μί PBS/NGS, 200 μί of 
40 mg/1 propidium iodide in PBS (Calbiochem, San Diego, Calif.) and 50 μί 1% 
ribonuclease A (Sigma, St Louis, Mo.) in order to measure DNA content per cell [11] 
simultaneously with the green fluorescence (GFL) of K,8.12- or RKSE60-positive cells. 
From each sample 5,000 cells were analyzed using an Ortho 50H flow cytometer 
equipped with a 5W Argon laser tuned at 488 nm as described by Van Erp et al. [17]. 
KjS.n- and RKSE60- positive cells were both determined in separate aliquots as GFL 
of GAM-FITC. DNA was quantified as red fluorescence (RFL) of propidium iodide. 
The right angle scatter signal was measured to correct for damaged cells. The data 
were stored in list mode and analyzed with a PDP 11/34 computer [11,14,17]. The 
percentages of cells in G,, S, and G2M phases were calculated with the standard 
program described by Baisch and Linden [18]. 
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Results 
Flow cytometric measurements of cell suspensions obtained from unstriped skin showed 
some bmding with K,8.12 in 3% of the cells, indicated by a low intensity of GFL. In 
contrast, all cell suspensions of stripped skin showed an increased percentage of K,8.12-
positive cells as well as an increased intensity of GFL. In general a gradual transition 
between K,8.12-positive and K,8.12-negative cell population was seen (Fig. la), but the 
threshold for positivity as to K,8.12 binding was defined based on samples with a clear-
cut bimodal distribution. All data of RKSE60-IabeIIed suspensions demonstrated a clear 
separation between positive and negative cells (Fig. lb). 
12Θ 128 
b RFL A 
Figure 1. Typical example of a flow cytometric analysis of epidermal cell suspensions RFL, representing 
DNA content, plotted against GFL, representing the binding of antibodies K
s
8 12 (a) and RKSE60 (b) 
The percentages of cells in SG2M phases, K,8.12- and RKSE60- positive cells (mean 
± SEM) were plotted against time-interval after stripping (Fig. 2). Figure 2a shows the 
percentage of cells in SG2M, which remained at a constant level (± 7%) during the first 
32 h. At 40 h after stripping the curve showed an abrupt increase up to 24%, while 
thereafter the percentage of SG2M-cells decreased gradually to about 18% at 72 h. 
Figure 2b shows the response of keratin 16 expression to standard trauma as measured 
by means of Kß 12 labelling. 
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Figure 2. Relative percentage of cells in SG2M phases (a) percentage of Kj^lZ-posilive cells (b) and 
pcrccnuge of RKSE60-positive cells (c) at different time intervals after sellotapc stripping (means ± 
SEM) 
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The curve in figure 2b shows an early increase, starting within the first 8 h, reaching 
significance after 16 h (Wilcoxon paired samples, P<0.01), while 24 h after stripping 
33% of the cells expressed keratin 16. After this time the percentage of K,8.12-positive 
cells decreased somewhat, but remained at a level higher than the initial value for at 
least 72 h. In Figure 2c the percentage of cells expressing keratin 10, assessed by 
RKSE60 showed no significant fluctuation during the first 40 h. At 48 h there was a 
statistically significant decrease (P<0.05 Wilcoxon ranking test for paired data), which 
showed a tendency to recover during the last 24h of the experiment. 
Because of the sharp rise of the SGjM and the Ks8.12 signals the time of 
appearance T S 0 2 M and Τ Κ ι β 1 2 are best defined as the moments the curves reach their 
half maximum. In contrast, the maximum itself is poorly defined due to the sustained 
plateau phase. Similarly, THKSE(i0 is the moment of reaching the half minimum of the 
RKSE60 signal. Table 1 summarizes the results of three time intervals after stripping as 
well as the differences between them. To exclude interindividual variation in the 
analysis, a comparison was done between the three parameters within the same 
individual, because these parameters are essentially paired data and as a result the 
SEM of the differences are sometimes lower than the SEM of the intervals itself. A 
statistically significant correlation was found between TS G 2 M and Τ^ν (Spearman 
correlation coefficient 0.84, P<0.01), but not between T^, ; , and Т
Я К 5 Е 6 0 or between 
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Tabic 1. (a) Times (mean ± SEM) of appearance or disappearance after sellolapc-slripping of SG2M, 
K
s
8.12 and RKSE60; (b) Time delays between the three signals (mean ± SEM). 
(a) time of (dis)appearance (b) time delay 
Signal Time (h) Delay Time (h) 
Τ^,π 18.0 ± 4 . 8 TW^Kse« 19.0 ± 2.8 
7SG2M 37.0 ± 3.6 Гнювю-Г»« 25.0 ± 11.7 
T W e o 43.0 ± 9.5 Грмао-Гвая, 6.0 ± 10.0 
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Discussion 
We have quantified separately the expression of keratins 10 and 16 in regenerating 
human epidermis. For this purpose we used the sellotape stripping technique and 
immunocytochemical labelling of epidermal cell suspensions, followed by flow 
cytometric analysis. With respect to the detection of keratin 16 it should be noted that 
the antibody K,8.12, which was used for this purpose, has been reported to react with 
both keratin 13 and 16. However, three arguments support our assumption that only 
keratin 16 is recognized in the epidermal cells examined by us. First, 
¡mmunohistochemical and biochemical data presented by several authors (e.g. [1,6,8]) 
have clearly shown that epidermal cells do not express keratin 13. Second, 
¡mmunohistochemical examinations by van Muijen et al. [9], using two different 
monoclonal antibodies specific for keratin 13 (1C7 and 1D7) have shown no reactivity 
with these reagents in normal epidermis. Third, using one of these two antibodies to 
keratin 13 (monoclonal antibody 1C7, a generous gift from Dr. van Muijen), we could 
not detect any reactivity in frozen sections of epidermis following sellotape stripping. 
The present study shows 1^8.12 binding in 3% of keratinocytes in normal skin. In its 
own right, these flow cytometric data might reflect false positive staining. However, a 
consistent pattern of Κ,8.12 staining, using ¡mmunohistochemical methods [5], indicates 
a limited expression of keratin 16 in normal skin. The difference in KJi.ll binding of 
normal skin between immunoblotting [1,8] and flow cytometrical techniques may be 
explained by the ability of latter techniques to detect relatively small numbers of 
positive cells. 
Keratin 16 expression was significantly increased as early as 16 h after tape-stripping 
and remained increased during the entire experiment. This is in line with the 
¡mmunohistochemical observations, showing marked basal and suprabasal binding of 
K,8.12 40 h and 64 h after tape-stripping [5]. The maximum of keratin 16 expression 
found after 24 h, coincided with that assessed by immunoblotting [1]. The percentages 
of cells in SGjM phases at different time intervals following tape-stripping show the 
classical pattern with a sharp increase after about 40 h [10]. Comparison of the mean 
values for the percentage of cells in SG2M and Κ,8.12- positive cells clearly indicates 
that the increase of keratin 16 expression precedes the regeneration of epidermis, 
assessed by DNA synthesis. Therefore, the increase of keratin 16 expression cannot be 
merely a consequence of hyperproliferation but rather indicates that this is a 'trigger' 
induced by a disturbed integrity of the epidermis, preluding the process of 
hyperproliferation. Analysis of these data on an intra-individual basis further 
substantiates this relationship. Although considerable variations between the individual 
curves of the volunteers as to both parameters were observed, the delay between both 
5 1 
TsG2M a n d Τ , ^
 1 2 for each individual appeared to be rather constant. Therefore keratin 
16 expression and DNA synthesis are related processes and as such might represent a 
cause-effect relationship or could be governed by the same first order process. The 
anticipation of biochemical changes in the suprabasal compartment regarding 
proliferative events in the basal compartment provokes speculation on the biological 
significance of chalones and growth-factors [19,20,21]. 
In contrast to the early response with respect to keratin 16 expression the 
percentage of cells expressing keratin 10 decreased much later. Therefore, the 
expression of keratin 16 cannot be caused by loss of keratin 10. This is further 
supported by the fact that the delay between Τ,^η a n d Τ , ^ ^ show no statistically 
significant correlation. Although hyperproliferative skin has a preference to express 
keratin 16 instead of keratin 10, the relative enlargement of the germinative cell pool 
might also contribute to the decrease of keratin 10 expression. This decrease is seen 8 h 
after the increase in DNA synthesis, at which time the first cohort of recruited cells has 
completed mitosis. 
In conclusion, keratin 16 expression, revealed by 1^8.12 binding, is an early event in 
the process of epidermal regeneration, suggesting the importance of biochemical 
changes in the suprabasal compartment in epidermal growth control. Further studies on 
metabolic events in this compartment are essential to clarify the control mechanisms 
involved. 
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4.2 Markers for proliferation and keratinïzatîon in the 
margin of the active psoriatic lesion 
S. de Mare, E. de Jong, P.E.J, van Erp, P.C.M. van de Kerkhof 
ВпіЫі Journal of Dermatology 1990; 122:469-476 
This work was presented at the 20"' annual meeting of the E.S.D.R., Turin, June 
9»,. j 2^ 1990 
To study the development of the psoriatic lesion, biopsies were taken from the margin 
zone of spreading plaques and acute pinpoint papules. Consecutive sections across the 
margin were stained using different monoclonal antibodies to characterize epidermal 
growth (Ki67) and (ab)normal keratinïzatîon (Κ,8.12, RKSE60). For comparison, the 
classical histological features such as inflammatory infiltrate, acanthosis and 
parakeratosis were studied. 
All three immunohistochemical markers showed pronounced changes in the lesionai 
skin with a clear transition to clinically uninvolved skin. The suprabasal K,8.12 binding 
was the earliest change found in the epidermis, and its localization high in the 
suprabasal compartment indicates that the metabolic dysregulation in this cell 
population is not a consequence of the recruitment process in the basal layer. 
Introduction 
hpidermal hyperprohtcration, abnormal keratinïzatîon and inflammation are well-
established features of the psoriatic lesion. There is a growing evidence that 
hyperpmhleration ol the epidermis in psoriasis is due to entry of quiescent (G0) cells 
into the cell cycle [1,2]. The majority of cycling cells can be identified by nuclear 
binding of the monoclonal antibody Ki67 [3], and an increased number of Ki67 positive 
nuclei has been shown in the psoriatic lesion [4]. The suprabasal cell layers also express 
markers linked to increased epidermal growth, such as keratin 16, which is 
demonstrated by the monoclonal antibody K,8.12 [5,6]. Although this antibody 
recognize keratin 13 as well, psoriatic epidermis does not express this keratin [7] In 
psoriasis, the clinically involved skin shows a marked staining of K,8.12, compared with 
uninvolved skin. The abnormal keratinization in psoriasis is characterized by the 
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presence of nucleated corneocytes and an absence of a granular layer. Keratin 10, 
which is involved in the normal keratinization process and can be visualized by the 
monoclonal antibody RKSE60 [8], is decreased in psoriasis [7,9]. This study investigated 
the position of these immunohistochemical markers for hyperproliferation (Ki67) and 
keratinization (1^8.12, RKSE60) during the evolution of the psoriatic lesion. 
Materials and methods 
Patients and biopsy procedures 
Ten patients (5 men, 5 women; aged 30-56 years) with chronic plaque psoriasis 
participated in this study. All patients were in an unstable phase of their disease, with a 
short history of new and extending lesions. This was confirmed by physical examination 
showing a pronounced erythema at the boundary of most plaques and presence of 
multiple pinpoint papules. Non of the patients received treatment for at least 2 weeks 
prior to the study. 
In five patients a biopsy was taken with a keratotome across the transition zone of a 
spreading psoriatic plaque containing both uninvolved and involved skin After cooling 
the skin surface with an ethylchlonde spray, a slice of 8 χ 16 mm was cut using a 
Castroviejo keratotome (depth 0.4 mm). In five patients a razor blade biopsy (diameter 
4 mm, thickness 0.5 mm) was taken from an acute pinpoint papule. Care was taken to 
ensure that the biopsy contained the whole papule and an annular zone of uninvolved 
skin. 
Immunohistochemical staining procedure 
All biopsies were washed in phosphate-buffered saline (PBS) and frozen immediately at 
-20oC in Tissue Тек II OCT compound (Miles Scientific, Naperville, USA). Three series 
of four consecutive sections of 6 μίτι were cut per biopsy. In each series, one section 
was fixed in 70% ethanol for 1 mm and stained with Hemacolor (Merck, Darmstadt, 
FRG). The remaining three sections were fixed in acetone-ether (60/40 v/v) for 10 mm 
and incubated with one of the following monoclonal antibodies: (1) 1^8.12 (Sigma, 
St Louis, MO, USA) diluted 1.40 in PBS, (2) RKSE60 (a generous gift of 
Dr F C.S.Ramaekers) diluted 1:10 in PBS, (3) Ki67 (Dakopatts, Copenhagen, Denmark) 
diluted 1-20 in PBS. The bound antibodies were visualized with a standard 
immunoperoxidase technique as described before [10,11]. After two washes with 
demineralized water, sections incubated with K,8.12 or RKSE60 were counterslained 
with haematoxylm (Mayer). All sections were mounted in glycerine gelatine and studied 
with a Leitz 12 light microscope. 
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Results 
The classical histological features of psoriasis appeared in a consistent sequence in the 
marginal zone of spreading plaques, (Fig. la). The predominantly mononuclear 
infiltrate was the most peripheral feature in four out of five biopsies. The development 
of acanthosis reaches an intermediate position, and parakeratosis had appeared after 
full acanthosis had been reached in all biopsies. The topographic relation between 
these histological features in pin point lesions is shown in Figure lb. It can be seen that 
in all pinpoint lesions the infiltrate preceded the full acanthosis. However, initial 
acanthosis was more widespread than the infiltrate in six out of 10 sites of the pinpoint 
papules. Again, the parakeratosis was seen centrally to the other histological features. 
~» 5 
full acanthosis _ r mm. epidermis surface 
Figure 1. The appearance of parakeratosis (1), increased Ki-67 nuclear staining (2), absolute and relative 
Ks8.12 staining (3), initial acanthosis (4) and infiltrate (5) in mm epidermis surface (mean ± SEM) 
related to the appearance of full acanthosis in the margin zone of spreading psoriatic plaques (A) and 
acute pinpoint papules (B). 
right side 
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The КІ67 staining in the margin zone of plaques and pinpoint papules showed a 
consistent well-defined change from cytoplasmatic and sporadic nuclear staining in the 
uninvolved skin to exclusively nuclear staining in the lesionai skin (Fig. 2a and 3a). The 
number of КІ67 positive nuclei was markedly increased in the lesion. In four out of five 
biopsies of the margin zone of the plaques and in eight biopsies of the pinpoint 
papules, the transition point of КІ67 was localized peripherally to full acanthosis but 
centrally to initial acanthosis (Fig.l). 
Suprabasal binding of Κ,.8.12 was observed only in the psoriatic lesion and changed 
gradually to patchy staining of the basal layers in normal looking skin (Fig. 2b).At the 
periphery of the suprabasal staining, there was no continuation between staining in the 
higher zones of the suprabasal compartment and the patchy basal staining (Fig. 3b). 
Figure 2. Histological overview of a representative pinpoint papules after staining with Ki-67 (a), K
s
8.12 
(h), KKSE60 (c). (x 100) 
SS 
Comparison of Κ,δ.ΙΖ binding and acanthosis is illustrated in Fig.l. Full suprabasal 
binding of KjS.ll occurred between initial and full acanthosis in all biopsies except in 
one case where it preceded the initial acanthosis. In three out of five biopsies of the 
margin zone of the plaque and in three biopsies of the pinpoint papules, both the initial 
and fully expressed K,8.12 binding coincided with the КІ67 transition point. The 
remaining biopsies showed binding of Κ,8.12 occurring peripherally to the КІ67 
transition point, with a marked separation between the initial and fully developed 
K
s
8.12 binding (Fig.l). 
Comparing binding of RKSE60 and K,8.12, a reversed staining pattern was seen 
with a minimal overlap between both staining patterns. RKSE60 binding was absent in 
the suprapapillary epidermis of the lesions, but the deeper regions of the rete ridges 
showed a normal RKSE60 binding with a gradually diminishing intensity towards the 
stratum corneum. This staining pattern was found only in the centre of the lesion. 
Figure 3. Details of the left margin of the pinpoint papule shown in Fig.2 after staining with Ki-67 (a) 
und K
s
8.12 (b).(x 400). Arrows in Fig.3b indicate patches of K
s
8.12 staining high in the suprabasal 
comparlment. 
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Discussion 
The margins of spreading plaques and early lesions such as pinpoint papules of 
psoriasis allow the study of different phases of development from penlesional to 
lesionai skin. In this model, the more peripheral changes are likely to play an early role 
in the pathogenesis. This study showed that the inflammatory infiltrate usually precedes 
the appearance of overt acanthosis, although in some cases these coincided. This 
observation agrees with several previous studies of pinpoint lesions [12] and the 
marginal zone of spreading plaques [13]. One study [14] reported that morphological 
changes in the epidermis preceded dermal changes, but details as to the nature and 
activity of the lesions were not reported. 
In the margin zone of lesions, the monoclonal antibody Ki67 showed a sharp 
transition point between 'uninvolved' and 'involved' psoriatic skin from a non-specific 
cytoplasmatic staining into a pronounced nuclear staining representing cycling cells [15] 
If psoriatic hyperprohferation is due to recruitment of resting basal cells, the change in 
staining pattern of K]67 might be expected before the development of acanthosis 
However, the Ki67 transition point was found between initial acanthosis and full 
acanthosis, which may be explained by a latency phase between the actual recruitment 
and the expression of the nuclear antigen for Ki67. Such a timelag has been 
demonstrated for lymphocytes [16] 
The relationship between epidermal hyperprohferation and abnormal keratimzation 
is still unresolved An earlier biochemical study showed that enzyme markers tor 
proliferation and keratimzation changed simultaneously in the margin zone of the 
spreading lesion [13] In this study, keratin 16 expression appeared as an early event in 
the margin of lesions before full acanthosis and even (in some lesions) before or 
coinciding with the initial acanthosis This is in line with the early expression of keratin 
16 following standardized injury [7] The isolated localization of the initial keratin 16 
expression high in the suprabasal compartment implies that these biochemical changes 
are not a consequence of metabolic events associated with the recruitment of G0-cells 
m the basal cell layer. We suggest that the changes in the suprabasal compartment are 
a link between the induction of regeneration and the recruitment process in the basal 
layer. Alternatively, both processes might be the consequence of a signal which is 
transduced to the basal and suprabasal compartment with a different time interval. 
The reverse staining pattern of RKSE60 compared to ΚβΛ2 indicates the possibility 
of a down regulation of keratin 10 caused by the induction of keratin 16 expression 
Such an inverse relationship between keratin 10 and keratin 16 has also been shown in 
other skin diseases [8] and regenerative epidermis [6,17]. However, this study 
demonstrates an interphase of simultaneous expression of both keratins 10 and 16, 
suggesting that both normal and hyperproliferative maturation pathways can exist 
60 
together Alternatively, the rate of disappearance of epitopes recognized by RKSE60 
might be of relevance in this respect. 
As the infiltrate was seen in the most peripheral zones of the spreading plaques and 
pin point papules, analysis of these cells using immunohistochemical markers might 
improve our understanding of pathogenesis of psoriasis Of all immunohistochemical 
parameters investigated in this study, the binding of Κ,812 in the suprabasal 
compartment represented the earliest event in the development of epidermal changes 
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Chapter 5 
DITHRANOL 

5.1 Outpatient treatment with short-contact dithranol: the 
impact of frequent concentration adjustments. 
S. de Mare, N. Calis, G. den Hartog, P.C.M, van de Kerkhof 
Acta Dermato-Venereologica (Stockh) 1989; 69:449-451 
Short-contact therapy with dithranol has become an important possibility for the 
treatment of psoriasis on an outpatient basis Two groups of patients with chronic 
stable plaque psoriasis were treated on an outpatient basis with a short-contact regime 
using dithranol in a stiffened paraffin base In one group the concentrations were 
adjusted once a week and in the other group 3 times a week Clinical results were 
evaluated using the Psoriasis Area Seventy Index. In the group of patients which was 
seen 3 times a week, the improvement was significantly better. The duration of the 
treatment period was significantly shorter compared to the group seen once a week due 
to the shorter time interval in which the optimal concentration of dithranol was 
reached. In addition, the incidence and seventy of irritation was more pronounced in 
the latter group 
Introduction 
During the last decade short-contact therapy with dithranol has reached the status of a 
classical treatment of psoriasis [1,2] Based on penetration studies Schaefer et al [3] 
reported that limited application periods might reduce side-effects in clinically 
umnvolved skin, whilst maintaining therapeutic potency in lesionai areas [4] Clinically, 
short-contact applications, varying between several seconds (On-off) up to one hour 
[3,5,6], proved to be comparable in efficacy to standard 24-hour application [7,8] The 
limited application periods permit treatment on an outpatient basis [9,10] Indeed this 
possibility has renewed the position of dithranol therapy amongst anti-psonatic 
treatments Although the value of short-contact therapy has been established in many 
studies, no consensus has been reached as to guidelines for outpatient management of 
dithranol treatment. Irritation of the skin prohibits frequent concentration increments 
However, if concentration increments are managed too cautiously, the treatment period 
is unacceptably long and the ultimate effectivity might be limited due to habituation or 
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poor patient compliance. 
In the present study, patients were treated with short contact therapy on an 
outpatient basis. Patients themselves or their partners applied dithranol daily on the 
skin lesions. Two protocols for outpatient dithranol treatment were compared, m which 
one group of patients was seen once a week (group 1/w) and the other group three 
times a week (group 3/w). Concentrations of dithranol were increased only at control 
visits. Clinical results (clearing and required treatment period) as well as side-effects 
(irritation and staining) of both groups were monitored in order to assess the effect of 
frequent concentration adjustments. 
Methods 
Patients 
Twenty six patients with chronic stable plaque psoriasis were selected from the 
outpatient clinic (15 men, 11 women, aged 18 - 70 years). All patients were untreated 
for at least one month with respect to topical medications and no systemic anti-psormtic 
medication had been taken during the previous year. The percentage of the body 
surface involved with psoriasis ranged from 5 - 60%. The patients were allocated at 
random in two groups. Each group was treated according to one of the following 
treatment protocols. 
Treatment protocoh 
The first group (16 patients) was treated on a weekly basis (group 1/w). Dithranol was 
applied daily by the patient himself, left on the plaques for 20 mm and subsequently 
removed using arachis oil and an acidic soap. To avoid drying of the skin, a bland 
emollient (aqueous cream) was applied after treatment. During the first week, all 
patients in this group used Psoncreme" (Essex, Amstelveen, The Netherlands) in 
concentrations of 0.1% (for 3 days) and 0.25% (for 4 days). During the following weeks 
increasing concentrations of dithranol (0.5%, 1%, 2%, 3%, 4% and 5%) were used in a 
base described by Seville [11] containing 2% salicylic acid, 30% paraffin solidum and 
supplied to 100% with vaseline album. At every control visit a decision was made 
whether the patient could use a higher concentration of dithranol or not. Criteria for 
remaining at the same concentration were signs of slight irritation, such as increased 
erythema of the plaque and surrounding skin. Patients were instructed to stop daily 
application with dithranol for 1 or 2 days if any irritation occurred. If such an 
interruption in the treatment occured, the patient was instructed to revert to a lower 
concentration until the next visit. If the maximum concentration of 5% was reached and 
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if no further improvement was seen for at least 2 weeks, the application period was 
extended to 30 min, 45 min, 60 min or overnight. The treatment was continued until 
total clearance was reached or a considerable improvement had occurred which was 
acceptable to the patient. 
The second group (10 patients) received the same instructions as to the daily use of 
dithranol at home. However, the patients were supervised intensively (3 times a week), 
which permits a faster increase of dithranol concentration. The concentration range of 
dithranol used in this group was also 0.1%-5%. Each patient in this group started with 
3 visits per week until the optimal concentration was reached. From this moment 
weekly controls were sufficient. 
Clinical evaluation 
Once a week, patients of both groups were examined in order to evaluate the clinical 
result. Scaling, erythema and induration were assessed clinically and scored on a 4-point 
scale (0-3). In addition, the extent of psoriasis was documented before and after the 
treatment period (Diagram 1). From the percentages of body surface involved and the 
clinical scores the Psoriasis Area Severity Index (PASI-score) was calculated [12]. 
Diagram 1. Psoriasis Area Severity Index 
Scale for erythema (E), induration (I) and Scaling (S): 
0 = no involvement 
1 = slight involvement 
2 = moderate involvement 
3 = severe involvement 
Scale for extent of psoriasis per body-area (A): 
Formula for PASI-score: 
1 = 1 - 10% 4 = 51 - 70% 
2 = 11 -30% 5 = 71 - 90% 
3 = 3 1 - 50% 6 = 91 - 100% 
head 0.1 χ (E+I+S) χ A + 
trunk 0.3 χ (E+I+S) χ A + 
upper limbs 0.2 χ (E+I+S) χ A + 
lower limbs 0.4 χ (E+I+S) χ A = 
PASI-score can range from 0 to 54 
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In order to express the relative improvement of the individual patient, the following 
equation was used· 
P A S I ^ - P A S U 
P A S I ^ . 
χ 100% = relative improvement 
The appearance of irritation and staining was monitored on a 3-point scale (-/+/++) 
Statistical analysis 
Paired and unpaired Wilcoxon ranking tests were used for statistical analysis. P-values 
less than 0 OS are statistically significant. 
Results 
The clinical improvement of both groups is summarized in table 1 Group 3/w showed a 
significantly better result as to improvement in PASI-score, compared to group 1/w 
(p<0 025). 
Table 1 Clinical results expressed as the number of patients showing different degrees of relative 
improvement Group 1/w n=16, group 3/w n=10 
Group <50% 50 - 90% >90% Drop-out 
1/w 4 6 5 1 
3/w 1 4 5 0 
The duration of treatment periods for both groups is shown in table 2 Both total 
treatment duration and time required for reaching the optimal concentration are 
significantly longer (p<0.003 and p<0 0001, respectively) in group 1/w compared to 
group 3/w. However, the treatment penods of both groups with the optimal 
concentration were not significantly different 
All patients, except for 3 in group 1/w and 1 m group 3/w, reached high 
concentrations of dithranol (3%-5%). In 3 patients of group 1/w and 6 patients of 
group 3/w the application period was extended to 1 hour and overnight application was 
only necessary in 1 patient of group 3/w Improvement was enhanced by these 
extensions 
Irritation, at concentrations of 1% or more, was seen in 9 of the 16 patients of 
group 1/w and in 4 of the 10 patients in group 3/w. In group 1/w, 2 patients showed 
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severe irritation. This caused one patient to withdraw from the tnal. Although irritation 
tended to be more frequent and severe in group 1/w, no statistically significant 
difference was observed compared to the more intensively monitored group. Staining 
occurred m 2 patients of group 1/w and in 4 patients of group 3/w, all in the last phase 
of treatment. 
Tabic 2 Duration of treatment periods in weeks (means ± SEM) t,,, = total treatment period, 
'/ncr= penod for reaching optimal concentration, t„, = period of treatment using optimal 
concentration 
Group 
1/w 
3/w 
4. 
11.7 ± 1 1 
73 ± 08 
tmc, 
6.7 ± 0 7 
2.4 ± 0 2 
W 
45 ± 06 
4.9 ± 0.8 
Discussion 
In the present investigation 33% of the patients seen at weekly intervals cleared 
compared to a clearing percentage of 50% for the patients seen 3 times a week Data 
from the literature amplify the impact of the frequency of control visits Hindryckx & 
De Bersaques [13] treated a group of patients at the outpatient clinic according to a 
similar short-contact dithranol regime, however, with control visits once per 1-3 weeks 
These authors reported clearing in only 10% and no effect at all in 35% of the patients. 
In contrast, a similar short-contact regime carried out at an inpatient department by 
Paramsothy et al yielded clearing in 62% of the patients [14] In the present study 
clinical improvement, assessed by the difference in PASI-score before and after 
treatment, proved to be significantly better in group 3/w compared to group 1/w 
Apart from the increased clearing capacity also a shortening of the treatment period 
was observed in group 3/w. The relatively long period before the optimal concentrations 
were reached in group 1/w (6.7 ± 0.7 weeks), is responsible in its own right for the 
elongated duration of the treatment in this group Between both groups no significant 
difference was observed as to the periods of treatment with the optimal concentration 
of dithranol. Therefore, the initial dose finding phase seems crucial for both treatment 
duration and clearing capacity. 
Although the patients of group 3/w were more prone to irritation due to a higher 
velocity of concentration increments, the incidence and severity of irritation was more 
marked in group 1/w. Therefore, intensified controls seem to be essential in order to 
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avoid undesirable irritation As the maximum irritation of dithranol is observed 
48 hours after application [15,16], dosage increments more frequently than 3 times a 
week could well result m a high incidence of irritation. Especially in ambulatory 
patients such should be avoided. Staining proved to be independent of the velocity of 
concentration adjustments, it rather seems to correlate with extended application times. 
Based on the present study, we may conclude that the frequency of control visits is 
essential in order to achieve an optimal therapeutical effect with high clearing and 
minimal irritation. It is most essential that patients are well instructed before starting 
dithranol therapy and that they are prepared for a time-consuming treatment. In this 
light, an educative attendance at an inpatient department or day-care centre might be <i 
valuable alternative. Anyhow, the first period of treatment requires intensified 
supervision in order to achieve optimal concentration adjustments and optimal patient 
compliance. 
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5.2 Dithranol in the treatment of inflammatory linear 
verrucous epidermal nevus 
S. de Mare, P.C.M, van de Kerkhof, R. Happle 
Acta Dermato-Venereologica (Stockh) 1989; 69:77-80 
A case of inflammatory linear verrucous epidermal nevus (ILVEN) is reported. Short 
contact treatment with dithranol resulted in complete relief from itching and a 
remarkable clearing of all linear lesions except from a small verrucous band on the 
shin. In patients with IL VEN it is advisable to try dithranol therapy before carrying out 
surgical procedures such as excision, cryotherapy, electrocautery. The prompt response 
to dithranol is best explained by the assumption that most of the lesions in this case of 
ILVEN represented true linear psoriasis. 
Introduction 
Inflammatory linear verrucous epidermal nevus (ILVEN) is a relatively rare but 
troublesome disorder. Based on the series of Altman & Mehregan [1] and a review of 
the more recent literature [2], the following criteria seem to be valid: 
(i) early age of onset; 
(ii) pruritic erythematous, slightly verrucous scaling of papules, which coalesce to 
linear plaques; 
(¡ii) histopathological features resembling those of psoriasis; 
(iv) persistent lesions showing marked refractoriness to treatment. 
The criterion 'resistence to therapy', is a generally accepted feature of this nevus [3]. 
11ère we report on a patient whose lesions responded well to dithranol treatment. 
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Case report 
A 44-year-old man presented with a severely itching linear skin disorder. At the age of 
12 years a linear reddish scaling lesion appeared on the left shin following a minor 
trauma. During the following years similar lesions occurred on the dorsal aspect of the 
left lower leg, spreading over the dorsomedial aspect of the upper leg, genital region 
and the lower thoracic and lumbal areas of the left side of his body. From the age of 25 
years onward the lesions had persisted without any response to treatment with UVB, 
PUVA and potent topical corticosteroid preparations. 
Physical examination revealed erythematosquamous plaques arranged in a linear 
pattern following the lines of Blaschko (Fig. la, 2a) [4]. On the left shin a slight 
verrucous aspect was seen. The erythematosquamous bands on the dorsomedial aspect 
of the left leg, genital region and lower half of the left side of the trunk had a more 
psoriasiform appearance. The finger nails showed multiple pits which appeared sharply 
punched out. On the scalp and on the extensor surfaces of the elbows sharply 
demarcated coin-sized erythematosquamous plaques were seen. 
A 4 mm punch biopsy from the lesion on the left shin showed acanthosis with 
elongation of the rete ridges. There were areas with hyperkeratosis of the orlhotype 
and areas with parakeratosis. The upper dermis showed a mild predominantly 
mononuclear infiltrate. Polymorphonuclear leucocytes were sparse and no exocytosis of 
these cells into the epidermis was seen. 
The patient was treated with dithranol according to a short contact schedule. 
Treatment was started with dithranol 0.1% and 0.25% in a cream base (Psoricream, 
Essex, Amstelveen, The Netherlands). The lesions in the genital region markedly 
improved on dithranol 0.25%. For the treatment of the lesions on the left leg and trunk 
the concentration of dithranol was increased twice weekly according to the range 0.5%, 
1%, 2%, 3%, 4% and 5%. Dithranol was applied in a stiffened paraffin base as 
described by Seville, containing 2% salicylic acid [5]. After 8 weeks of treatment 
maximal improvement was reached (Fig. lb, 2b). The troublesome pruritus had 
disappeared totally and a remarkable improvement up to virtually total clearing was 
reached in all areas with the exception of a verrucous zone on the shin that persisted 
virtually unchanged. 
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Figure 1. Erythematosquamous plaques in a linear distribution on the trunk, (a) before treatment, (b) 
after treatment with dithranol. 
Figure 2. The dorsal aspect of the left lower leg, showing erythematosquamous lesions in a linear 
distribution, (a) before treatment, (b) after treatment with dithranol. 
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Discussion 
The skin lesions in the present case fulfil the criteria for diagnosis ILVEN: (i) onset 
before puberty; (ii) pruritic sensation and typical clinical appearance; (iii) psoriasiform 
histological features; (iv) resistance to topical corticosteroids, PUVA and UVB 
treatment. However, treatment with dithranol -a therapy which is effective specifically 
in psoriasis and seborrhoeic dermatitis- proved to be effective in all linear lesions 
expect for a limited area on the shin. From a clinical point of view a diagnosis of linear 
psoriasis would be acceptable for most of the linear lesions in the present case. The 
presence of signs of psoriasis in other areas (nails, elbows, scalp) further supports this 
diagnosis. 
In the past, many authors have discussed the nosological significance of the ILVEN. 
It has been argued that at least some cases of ILVEN represent true linear psoriasis 
[6,7,8]. In two of these cases [6,7] classical manifestations of psoriasis were seen on the 
other skin sites and in all 3 cases antipsoriatic therapies such as chrysarobin, tar and 
ultraviolet radiation resulted in complete clearing of the lesions. Alternatively, an 
epidermal nevus of the common non inflammatory type may constitute a site of 
predilection for psoriasis as described by Sugai et al.[9] and Bennett et al.[10]. 
Theoretically, the clinical and histological appearance of such a case may be 
indistinguishable from classical ILVEN. In the case reported by Bennett et al.[10] the 
systematized nevus adopted a psoriatic appearance and typical psoriatic lesions were 
seen on other sites. Treatment with dithranol resulted in resolution of the typical 
psoriatic lesions, whereas the linear lesions remained unaffected. Ogino and Higuchi 
[11] described a patient with generalized pustular psoriasis associated with ILVEN. 
With methotrexate an almost complete clearance of the pustular psoriasis was achieved. 
However, pustule formation remained within the nevus, indicating that ILVEN might 
represent a 'locus minoris resistentiae' to psoriasis. A third subclass of ILVEN may be 
ILVEN sui generis [1,2,12,13]. This subclass has been claimed to be remarkably resistant 
to topical treatment. 
The present case apparently represents a manifestation of true linear psoriasis, 
extending far beyond the clinical boundaries of 'ILVEN sui generis' (localized on the 
left shin). This case demonstrates that the ILVEN is not only a site of predilection for 
superimposing psoriasis [9,10,11], but that even new psoriatic lesions may develop in 
linear zones following the lines of Blaschko. A similar distribution of linear psoriasis 
outside the limits of an epidermal nevus has been described by Bondi [14]. This 
distribution is not at random but arranged according to the lines of Blaschko that 
visualize the migration of mutant cells derived from a small group of stem cells during 
embryogenesis [15]. 
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The present observation indicates that therapeutical defeatism in the management 
of patients with ILVEN is not always justified. As some cases may represent true linear 
psoriasis, an attempt to treat the lesions with dithranol seems worthwhile. 
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53 The relevance of salicylic acid in the treatment of plaque 
psoriasis with dithranol creams 
S. de Mare, N. Calis, G. den Hartog, P.E.J, van Erp, P.C.M. van de Kerkhof 
Skin Pharmacology 1989; 4:459-464 
The relevance of salicylic acid in dithranol creams was evaluated in a double blind 
study. Patients with chronic plaque psoriasis were treated using a short contact schedule 
for dithranol on an outpatient basis. A left-right comparison was carried out between 
sites treated with either dithranol with 2% salicylic acid (D+S) or dithranol in the same 
base without salicylic acid (D-S). Clinical results were evaluated once a week using the 
Psoriasis Area Severity Index (PAST). In order to quantify the improvement, flow 
cytometric measurements were done using the monoclonal antibody ΚβΛ2, recognizing 
keratin 16 in normal and lesionai epidermis. Simultaneously, relative DNA content was 
quantified which previously was described as a useful method to monitor a therapeutic 
effect. 
Both PASI-scores and ΚβΛ2 binding decreased after 6 weeks treatment with D+S 
and D-S. However, percentages of cells in SG2M phases did not show a significant 
change. No significant difference was observed between sites treated with either D+S 
or D-S. Therefore we conclude that the addition of salicylic acid in a concentration of 
2% does not enhance the efficacy of dithranol creams and confirm that 1^8.12 is a 
useful quantitative marker for therapeutic efficacy. 
Introduction 
It is well established that the addition of salicylic acid in concentrations up to 2% 
prevents inactivation of dithranol by zinc oxide [1,2]. Zinc oxide is one of the essential 
components of Lassar's paste, the classical base for dithranol therapy [3]. However, in 
other vehicles, such as paraffin, vaseline or creams, the preservative effect of salicylic 
acid has never been proven [4,5]. An enhancement of the penetration of other 
pharmaca has been demonstrated with salicylic acid in concentrations of 10% or more 
[6]. Up to now such effect has never been shown for the lower concentrations of 
salicylic acid. 
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In the present investigation the relevance of salicylic acid in dithranol cream was 
studied m a short-contact schedule. A left-right comparison was carried out on 
outpatient basis between sites treated with either D+S or D-S. Based on a previous 
study the initial frequency of control visits was 3 times a week until the individual 
optimum of dithranol concentration was found, after this concentration was reached, a 
control visit once a week proved to be adequate [7]. The clinical efficacy was monitored 
using the Psoriasis Area Seventy Index (PASI). From both sites biopsies were taken 
before and after treatment in order to quantify keratin 16 expression [8,9] and relative 
DNA content using flow cytometry The reduction of keratin 16 has been claimed to be 
a reliable marker for the resolution of the lesion during treatment with dithranol [10] 
Measurement of relative DNA is a direct reflection of epidermal growth and this 
parameter also has been shown to parallel the clinical improvement during dithranol 
therapy [11]. 
Methods 
Patients 
Twenty patients (9 men, 11 women, aged 18-64 years) with chronic stable plaque 
psoriasis participated in this study after giving informed consent. The percentage of 
body surface involved with psoriasis varied between 5% and 60% During at least 
2 weeks before entering the trial, patients discontinued their topical medication. No 
systemic anti-psonatic medication was taken during the last year. 
Treatment protocol 
The study design was a double-blind comparison between sites treated with D+S versus 
D-S. Patients were treated on an outpatient basis using a short-contact schedule [12,13] 
In brief, dithranol was applied daily, left on the plaques for 20 mm and washed off 
subsequently with water and acidic soap. In order to avoid exsiccation of the treated 
sites a bland emollient was applied after the dithranol application 
All patients started with dithranol 0 5% in two different cream bases (D+S/D-S, 
Psoralon", Hermal, Hamburg, FRG). At the control visits the concentration ot dithranol 
was increased at both sites (1%,2%,3%), if no signs of irritation had occurred In order 
to find out the optimal concentration of dithranol, each patient was seen 3 times a 
week [7] After the optimal concentration was reached the patients were seen at weekly 
intervals 
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Skin sampling 
Before treatment razor blade biopsies (average thickness 0.5 mm, diameter 4 mm) were 
taken [14] from 2 symmetrical lesions. After a treatment period of 6 weeks again 2 
biopsies were taken from the same areas. Epidermal cell suspensions were prepared 
directly using a trypsinization procedure as described by Bauer et al [11]. The 
epidermal cell suspensions were fixed in 70% ethanol and stored at -2(PC until use. 
Analytical procedures 
An aliquot of 500 μ\ cell suspension was rehydrated in phosphate buffered saline (PBS) 
containing 1% normal goat serum (NGS; Sera-lab, Sussex, England) and labelled using 
an indirect immunofluorescence technique [8,9]. In brief, cells were incubated with 
monoclonal antibody 1^8.12 (Sigma, St Louis, MO) diluted 1:30 in PBS/NGS. As 
second antibody a FITC conjugated goat anti mouse IgG was used, diluted 1:25 in 
PBS/NGS. Finally, the sediment was resuspended in 200 /J PBS/NGS, 200 pi PBS 
containing 8 mg propidium iodide (Calbiochem, San Diego, CA) and 
50 μ\ 1% ribonuclease A (Sigma, St Louis, MO) was added in order to measure relative 
DNA content per cell [14] simultaneously with the green fluorescence of К Д П * cells. 
Five thousand cells of each sample were analyzed using an Ortho 50H flow cytometer 
equipped with a 5W Argon laser tuned at 488 nm as described by Van Erp et al [8]. 
The data were stored on and analyzed with a PDP 11/34 computer [8,9,14]. 
Statistical analysis 
A Wilcoxon ranking test for paired data was used for comparison of the results on 
D+S and D-S treated sites. P-values less than 0.05 will be declared significant. 
Results 
In 18 patients the optimum concentration of dithranol proved to be 3% and in 2 
patients an optimum concentration of 2% was reached. 
The clinical score before and after treatment with D+S and D-S are shown in 
Fig. la. Seven patients showed a complete clearance, 7 patients were almost cleared and 
in one patient with extensive psoriasis a marked improvement was observed. Two 
patients showed a slightly better improvement in PASI-score on the D+S-treated site 
(patient A: 6.6; patient B: 1.6) than on the D-S-treated site (patients A: 6.0; patient B: 
1.2). In patient A this difference was due to the parameters desquamation and 
erythema. In patient В it was due to induration and erythema. One patient responded 
better on the D-S treated site (an improvement of 3.9 versus 3.6). This difference was 
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PASI-score + / - SEM 
a Time in weeks 
7. Кз l2-posiUve cells + / - SEM 
Time in weeks 
Я cells In SG2M-phase + / - SEM 
Time in weeks 
I +SAL I I -SAL 
Fig 1. Changes in parameters before and after a treatment period of 6 weeks comparing diihranol creams 
with and without the addition of salicylic acid, (mean values) 
a) Psoriasis Area Severity Index (PASI). 
b) Percentages of KjS.n-positive cells. 
c) Percentages of cells in SG2M phases. 
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due to induration only. Comparing all data, no signiñcant difference between D+S and 
D-S-treated sites was observed. 
The clinical responses to dithranol of the biopsy sites showed some interindividual 
variation. In 7 patients the biopsy sites were totally healed, in 8 almost healed, in 4 
markedly improved and in 2 patients only a slight improvement was observed. Parallel 
to the clinical resolution a reduction of keratin 16 expression was found (fig lb.). Again, 
no significant difference occurred comparing the D+S and D-S treated sites. 
The percentages of cells in the SGjM phases were not significantly changed after 6 
weeks of treatment. Again, both treatment-sites did not differ in this respect (fig l a ) . 
Means ± SEM of all data are summarized in table 1. 
Irritation in terms of erythema of the surrounding skin or a sensation of burning 
occurred in 2 patients. The degree of irritation was similar for both treatment-sites. 
Table 1 Means ± SEM of clinical scores and parameters for epidermal growth before and after 
ircaimcni. 
D+S D-S 
PASI-score 
before 
after 
% Кз8.12+ cells 
before 
after 
% cells in SG2M phase 
before 
after 
7.9 ± 1.3 
2.5 ± 0.6 
39.1 ± 4.3 
16.6 ± 2.1 
13.1 ± 0.5 
14.3 ± 1.3 
7.7 ± 1.4 
2.4 ± 0.6 
44.0 ± 4.6 
24.8 ± 4.0 
13.7 ± 0.3 
14.3 ± 1.3 
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Discussion 
The short-contact therapy with Psoralon" on outpatient basis proved to be practical. 
Patient compliance during the treatment was relatively high compared to the same 
treatment schedule with dithranol in the stiffened paraffin base [7]. Although the 
treatment schedule was time-consuming for the patients, the fact that the cream 
(Psoralon") can be washed off easily was experienced as an important advantage above 
the stiffened paraffin base. It is of interest that no drop-outs could be reported in this 
study. Based on a treatment period of 6 weeks the concentration-range up to 3% was 
adequate. However, in 2 out of 7 patients, who continued treatment beyond the 
experimental period, a prolonged application time of 1 hour was necessary. Probably 
the restoration of the stratum corneum might decrease the bio-availability of dithranol 
in the later phase of treatment [15,16]. 
The expression of keratin 16 in untreated lesionai skin has been reported to be 
substantially increased (10%-60% of the cells expressing keratin 16) compared to the 
uninvolved skin of psoriatic patients and healthy volunteers (<5%) [8,9]. This large 
range permits quantification of the intermediate stages between clinically involved and 
uninvolved skin. Indeed, Holland and coworkers [10] reported a reduction of keratin 16 
expression during treatment with dithranol, using SDS gel electrophoresis. In the 
present investigation these data are confirmed by flow cytometrical quantification on a 
cell by cell basis. However, in totally cleared lesions the expression of keratin 16 was 
still above the normal level (10.8 ± 1.9). This is in line with preliminary observations 
from our group showing induction of keratin 16 expression in normal healthy 
volunteers (12.9 ± 2.7) after dithranol application [unpublished data]. 
Relative DNA content per cell is a direct reflection of cell cycle kinetics. Compared 
to the expression of keratin 16, the range between clinically involved (12.6 ± 0.8) and 
uninvolved skin (5.6 ± 0.5) was relatively small [14]. In the present study no significant 
change in relative DNA content was found during the treatment, indicating that a 
clinically cleared plaque still might be profoundly abnormal from a cell cycle kinetic 
point of view. A sampling error can be excluded for this unexpected finding, as keratin 
16 decreased markedly in the same biopsies. An attractive explanation for this 
observation is provided by the fact that dithranol inhibits DNA replication [17,18] and 
arrests cells in S phase. This results in a decreased ['HJthymidine uptake as reported in 
literature [19,20] and an unchanged number of cells in S phase as observed in the 
present study. The discrepancy between persistent hyperproliferation and decreased 
keratin 16 expression following treatment with dithranol suggests that the expression of 
this keratin is not directly linked with hyperproliferation, but is rather a marker for a 
more general disturbance of epidermal integrity. 
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In the present study the clinical resolution of the lesions was not enhanced on the 
sites ireated with D + S compared to the sites treated with D-S. As to the induction of 
irritation, the addition of salicylic acid did not influence the response; in the 2 patients 
showing irritation no difference was seen between both sites. From a cell kinetic point 
of view the clinical impression is confirmed: there is no significant difference between 
the two sites. 
In conclusion the addition of salicylic acid to dithranol cream (Psoralon") in a short-
contact schedule does not influence the therapeutical efficacy. 
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Chapter 6 
VITAMIN D3 

6.1 Active vitamin Dj does not suppress recruitment of G0 
cells following injury 
M G.J. van Bokhoven, S. de Маге, В M. Czametzki, Р.Е J van Erp, J Β M 
Boezeman, P.C.M, van de Kerkhof 
British Journal of Dermatology 1988; 119:737-742 
This work was presented at the IS"7 annual meeting of the E.S.D.R., Munich, 
June І^-гг*, 1988 
The effect of topically applied active vitamin D 3 on epidermal regeneration was studied 
in eight healthy volunteers following sellotape stripping. 
The mobilization of resting (G,,) cells was assessed by means of DNA flow 
cytometry, using a narrow window in the mid-S phase to monitor the progress of the 
recruited cells. Although vitamin D 3 was applied at a concentration exceeding the range 
reported to be effective in psoriasis, we were unable to find any effect of active vitamin 
D 3 on G0 mobilization m vivo. 
Introduction 
Topical application of active vitamin Од, either as lo,25-dihydroxycholecalciferol 
(1,25-DCC) or as lo,24-dihydroxycholecalciferol, with or without occlusion, has been 
reported to be effective in the treatment of psoriasis [1,2,3]. Reports that these 
substances inhibit the proliferation of keratinocytes both in culture [4] and in an animal 
model in vivo [5] strongly suggest that the antipsonatic effects may be mediated by the 
normalization of epidermal cell cycle kinetics. 
It has recently been established that an epidermal injury, such as sellotape stripping, 
causes the recruitment of resting (G,,) keratinocytes, and hence provides a useful model 
for the hyperproliferative aspects of psoriasis [6]. In the present study we have used 
this model to establish whether or not 1,25-DCC suppresses G 0 mobilization in human 
skin. 
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Methods 
Subjects 
Eight paid volunteers (four males and four females, aged between 20 and 28 years) 
with no history of skin disease, took part in this study. Clinical and laboratory 
examination were carried out at the start of the study to confirm that the subjects were 
in good health and laboratory examination were carried out at the end of the study to 
exclude any intercurrent laboratory abnormalities. 
Experimental procedure 
In this randomized double blind study, 1,25-DCC (Hoffmann-La Roche & Co. Basel, 
Switzerland) at a concentration of 2 /ig/ml in medium chain triglyceride, or medium 
chain glyceride base only, was applied twice daily for 1 week to six sites on the back of 
each subject. Each site measured approximately 2 cm2. About 0.2 ml of the solution was 
spread over each of the six sites with the stem of a pipette and allowed to dry for about 
5 min. On day 9, after a 24 h rest period, the sites were stripped with adhesive tape 
until the wet, glossy stratum granulosum appeared (usually after 35-45 applications of 
tape). Treatment was resumed immediately thereafter and continued at 12 h intervals 
up to the time at which the site was biopsied. Biopsies were taken from each site 26, 
40, 44, 48, 52 and 56 h after stripping and processed for examination by DNA flow 
cytometry. The procedure was repeated one month later in each subject with the 
alternate test solution. Medical Ethical Committee approval was obtained prior to the 
experiments. 
Sample preparation and DNA staining 
The biopsies were taken with a razor blade in conjunction with a metal guard [7] and 
immediately transferred to phosphate-buffered saline (without Ca and Mg, pH 7.2-7.4, 
Seromed L-1825). Samples measured approximately 6 mm2 with an intradermal depth 
of 0.3 mm. 
Biopsies were processed for cell cycle kinetic studies as described previously [7]. 
Briefly, the skin specimen was incubated in trypsin, DNA stained with propidium iodide 
and filtered for flow cytometry. 
Flow cytometry 
Cell cycle analysis was performed using a flow cytometer 50H (Ortho Instruments, 
Westwood, MA, U.S.A.) equipped with a 5W argon ion laser (164-05, Spectra Physics, 
Mountain View, CA, U.S.A.). The PI fluorochrome was excited at the 488 nm laser line 
and the fluorescence was measured with a high-pass filter RG 630 (Melles Griot, 
ββ 
Zevenaar, The Netherlands). At least 50.000 cells were counted, at 200-500 cells/s. The 
data were stored and analysed with a PDP 11/34 computer (Digital Equipment, Galway, 
Ireland). Both the area and the peak value of each fluorescence signal were measured. 
Analysis of the changes brought about by tape stripping was based on the apparent 
changes in cell numbers at different points in the cell cycle [6]. Briefly, a 'window' was 
selected in the histogram. This was set relative to the position of the peak of diploid 
cells as shown in figure 1. The occupation of this window could be determined at the 
different times after stripping and data could be plotted to determine the time of 
maximal occupation, the height of maximal occupation and the total size of the 
recruited cohort of cells. 
Counts 
DNA 
Figure 1. The distribution of diploid and tetraploid cells is shown. The window covers the maximum of 
cells in mid-S phase. 
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The total size of the cohort of recruited cells could be determined in two different 
ways. First, by means of integration of the data shown in figures 2 and 3. The 
integration was performed by the using the following formula [6]: 
ίΤ*ν 
N « , ^ = summ.iNrN,^) 
sw 
where 
sT = sample interval time, 
ν = velocity of the recruited cells passing through the window, 
«W = width of the window, 
N, = percentage of cells in the window at time t„ 
Nnomi = control percentage of cells in the window at time t,, 
Secondly, the minimal percentages of recruited cells could be determined by 
measuring the percentages of cells in S and G 2 together in the individual histograms at 
the time of maximal window occupation. From that the means ± SEM could be 
determined. This results in an under-estimate, the real percentages being much higher. 
Results 
No clinical side-effects and no laboratory abnormalities were observed during the study. 
In particular, no abnormalities in serum calcium levels were found. 
The mean percentages of cells (± SEM) in window 1 (mid-S phase) at the different 
time points are given in figures 2 and 3. Figure 2 shows results after treatment with 
1,25-DCC and figure 3 results after treatment with the base only. 
Using the above formula, and given that sT = 4 h, ν = 1/duration of S phase = 1/8 
h, and sW = 0.2, we calculated that the mean percentages of the total cohort of 
recruited cells (mean and SEM) were 44 ± 7.5% for the 1,25-DCC treatment and 39 ± 
7% for the base treatment. We determined the mean minimal percentages of recruited 
cells (± SEM) as 22 i 2% for the 1,25-DCC treatment and 24 ± 2% for the base 
treatment. 
As can be seen from figures 2 and 3, 1,25-DCC does not delay but tends to 
accelerate the growth of the cohort of cells through the cell cycle. However, no 
significant changes could be shown in the time of maximal occupation, nor in the height 
of the cohort of cells (ANOVA; p>0.05). 
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Figure 3 Percentage of cells in S phase (mean ± SEM) at diffcrem lime intervals following sellotape 
stripping of skin pretrealed with the base only 
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Discussion 
The present investigation clearly shows that there is no significant inhibition of trauma-
induced epidermal regeneration of human skin by 1,25-DCC. There was no change in 
time of maximal occupation, in height of the peak of maximal occupation or in the total 
size of the cohort of recruited cells. This observation is surprising in view of the 
successful treatment with active vitamin D3 reported by several investigators [1,2,3]. 
One explanation for the discrepancy between our observation and the successful 
treatment of psoriasis with 1,25-DCC could be a suboptimal bioavailability of the drug 
in our study. However, in the present study 1,25-DCC was applied twice daily, whereas 
the substance was applied once daily in a successful clinical study [1]. The concentration 
of 1,25-DCC used in the present study is at least four times higher than the 
concentration range used in the clinical trials [1,3], the latter being in the range of 
0.1-0.5 /ig/g petrolatum. In the present investigation we did not use occlusion to 
enhance penetration of 1,25-DCC. However, one of the clinical studies claimed 
excellent results without occlusion [2]. Drug penetration through intact stratum 
corneum is lower than the penetration through the parakeratotic horny layer of the 
psoriatic lesion. However, during successful treatment, the skin barrier recovers 
relatively early. As 1,25-DCC was also applied immediately after Sellotape stripping, 
from 26 to 56 h, good penetration, probably even better than through a psoriatic lesion, 
was possible. Therefore, decreased bioavailability is very unlikely to be the explanation 
for the discrepancy between the clinical efficacy of 1,25-DCC and its lack of effect in 
the Sellotape stripping model. 
The discrepancy between our findings and the reported antipsoriatic effectivity of 
1,25-DCC might be explained by the possibility that tape stripping of normal skin is not 
a good model for testing the effects of drugs which exert their clinical effects mainly in 
stable plaque psoriasis. Different 1,25-DCC receptor binding or interference by growth 
factors might be of relevance in this respect. In the suprabasal layers of the epidermis 
of the psoriatic lesion a two-fold increase of the binding capacity for epidermal growth 
factors has been observed compared with normal skin [8]. It is not known whether the 
cytosol binding of 1,25-DCC in the lesionai skin is comparable with that in normal skin. 
The binding capacity for growth factors and 1,25-DCC following Sellotape stripping are 
completely unknown. It has been shown in cultures of fibroblasts that 1,25-DCC only 
modulates growth of cells exposed to growth factors [9]. In keratinocytes and fibroblasts 
an intracellular receptor for 1,25-DCC seems critical for the metabolic effect of this 
drug [10]. Alternatively, calcitriol might normalize differentiation of keratinocytes in 
stable plaques and only indirectly affect recruitment of cells into the cell cycle. 
Another explanation might be that the antiproliferative effect of calcitriol, as 
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observed in vitro and in animal experiments [4,5] is not the antipsonatic working 
mechanism for these drugs. An effect of these drugs on the immmune system has been 
described. For example, interleukin-l and interleukin-2 induced murine thymocyte 
proliferation is inhibited substantially by 1,25-DCC [11]. An effect of 1,25-DCC on 
polymorphonuclear leucocytes might be hypothesized. In the past vitamin D 2 has been 
reported to be effective in pustular psoriasis [12]. 
Another possible explanation for the discrepancy is that calcitriol only has a placebo 
effect on the psoriatic lesion. Until now only open studies on the effect of these drugs in 
psoriasis have been carried out; controlled double blind studies are urgently needed. 
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6.2 DNA content and КД12 binding of the psoriatic lesion 
during treatment with the vitamin D3 analogue MC903 
and betamethasone 
S. de Mare, E.G.J.M. de Jong, P.C.M. van de Kerkhof 
British Journal of Dermatology 1990; 123:291-296 
This work was presented at the Iti* annual meeting of the E.S.D.R., Turin, June 
Э
1
* - IZ*, 1990 
A group of 20 patients was treated with the novel vitamin Dj analogue MC903 and 
betamethasone ointment in a double-blind trial with a left-right comparison. In addition 
to the clinical severity scores Kß.Xl binding which detect keratin 16 expression and 
DNA synthesis were quantified using flow cytometry. Both proliferation markers 
decreased significantly with treatment but remained elevated above the normal range 
even in those patients who had total clearance of the lesions, indicating that these 
parameters extend the observation into the apparently clinically uninvolved range. 
Treatment with MC903 resulted in a statistically significant advantage above 
betamethasone treatment, using 1^8.12 binding as cell biological parameter. 
Introduction 
Psoriasis is a very common skin disorder characterized by increased epidermal cell 
proliferation. It is a well-established fact that active vitamin D3 (la,25-(OH)2-D3) 
inhibits epidermal proliferation in culture [1]. Vitamin D3 is also claimed to be effective 
in the treatment of psoriasis based on open studies [2,3]. Recently, a new vitamin Ό3 
analogue, MC903, has been found to be as potent as la,25-(OH)2-D3 in inhibiting 
epidermal proliferation. It is, however, 100 times less active than la,25-(OH)2-D3 as 
regards its effect on calcium metabolism [4]. Therefore, it can be applied in higher 
concentrations compared to lo,25-(OH)2-D3. It has also been shown in a double-blind 
study that MC903 in concentrations of 10/ig/g or greater is effective in the treatment of 
psoriasis [5]. 
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The aim of the present study was to assess the effectiveness of MC903 in the 
treatment of psonasis compared with betamethasone by measuring binding of К.Д12 
and DNA content using flow cytometry [6,7,8]. The clinical efficacy was monitored using 
the Psoriasis Area Severity Index. These data will be included in a publication of a 
multi-centre trial [9]. 
Methods 
Patients 
Twenty patients (10 males and 10 females, age range 20-79 years) with chronic stable 
plaque psoriasis participated in this study after giving informed consent. The percentage 
body surface involved with psoriasis ranged from 5-30%. In the 8 weeks before starting 
the trial none of the patients had used systemic treatment for their psoriasis or 
ultraviolet light therapy. For at least 2 weeks before treatment no topical antipsoriatic 
therapy was used. Patients on systemic drugs and with renal diseases, hepatic 
impairment or abnormal calcium metabolism were excluded from this study. 
For a period of 2 weeks the patients applied a bland emollients only to the affected 
areas. During the treatment, on one side of the body MC903 ointment (50 mg/g) and 
on the other side betamethasone (0.1%) was applied 2 times per day. Both ointments 
were not applied on the face, scalp and genital region. The design of the study was a 
double-blind comparison. During the treatment period, patients were monitored by 
clinical assessment and blood investigation at regular intervals. The efficacy of the 
treatments was assessed using the PASI-score and clearance was assessed as complete 
resolution of the lesions apart from a residual discoloration. 
Skin sampling 
Before treatment razor blade biopsies (average 0.5 mm thick, 4 mm in diameter) were 
taken from two symmetrical lesions. After a treatment period of 6 weeks, two further 
biopsies were taken from the same areas. Epidermal cell suspensions were prepared 
directly using a trypsinization procedure as described previously [8]. The cell 
suspensions were fixed in 70% ethanol and stored at -20oC until use. 
Analytical procedures 
An aliquot of 500 μΐ cell suspension was rehydrated in phosphate-buffered saline (PBS) 
containing 1% normal goat serum (NGS; Sera-lab, Sussex, England) and labelled using 
an indirect immunofluorescence technique [6,10] In brief, cells were incubated with 
monoclonal antibody Κ,8.12 (Sigma, St.Louis, MO) diluted 1:30 in PBS/NGS. As second 
antibody, a FITC conjugated goat anti mouse IgG was used, diluted 1:25 in PBS/NGS. 
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Finally, the sediment was resuspended in 200 μ\ PBS/NGS, 200 μ\ PBS containing 8 mg 
propidium iodide (Calbiochem, San Diego, CA) and 50 μ\ 1% ribonuclease A (Sigma, 
St. Louis, MO) was added in order to measure relative DNA content per cell [11] 
simultaneously with the green fluorescence of K,8.12 positive cells. 
Five thousand cells of each sample were analyzed using an Ortho 50H flow 
cytometer equipped with a SW Argon laser tuned at 488 nm as described by Van Erp 
et al [б]. The data were stored on and analyzed with a PDP 11/34 computer [6,10,11] 
Statistical analysis 
A Wilcoxon rank test for paired data was used for comparison of the results from the 
MC903 and betamethasone treated sites. P-values less than 0.05 were considered to be 
significant 
Results 
Both MC903 and betamethasone ointments resulted in clearance of the lesions in eight 
out of the 20 patients. A mild improvement was seen in five patients and a moderate 
improvement in seven. As with the clinical response, K,8.12 binding and DNA content 
reduced significantly (p < 0.01) as a result of both treatments (Fig.la-b) The values in 
these three groups as determined by their clinical response to MC903 or 
betamethasone are shown in table 1. [6,12]. 
Table 1 Mean (± SEM) values of parameters for epidermal growth in biopsies after treatment with 
MC903 or betamethasone Patients are subdivided according to their clinical respons Values for normal 
skin and psoriatic umnvolved skin arc included as a reference 
clinical appearance % Κβ 12+ cells % cells in SGyM-phase 
total clearance 8.4 ± 1 . 5 6.6 ± 0.4 
moderate improvement 19.5 ± 3.3 7.1 ± 0.6 
mild improvement 29 8 ± 6.8 12.4 ± 1.4 
normal skin 1.8 ± 1.0 [6] 4.0 ± 0.7 [12] 
umnvolved skin of psoriatics 1.0 ± 0.2 [6] 5.6 ± 1.1 [12] 
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Figure 1. Markers for epidermal growth before treatment and after treatment (means ± SEM): 
(a) percentage of K,8.12 positive cells 
(b) percentage of cells in SG2M-phases 
98 
Comparing the МС90Э treated sites with the betamethasone treated site with 
respect to K^S.ll binding, a lower average value was found of the MC903 treated site, 
although the difference was not statistically significant. However, analyzing the 
reduction of 1^8.12 binding during treatment, a statistically significant difference was 
found in favour of the MC903 treatment (p < 0.05). The reduction of DNA content 
showed no statistically significant difference between the two treatments. Following 
treatment, the patients that had clearing of the lesions had a significantly lower 1^8.12 
binding (p < 0.03) and DNA content (p < 0.05) compared to the other patients. 
However, these parameters were still increased above the normal range. 
Discussion 
This study confirms that the vitamin D 3 analogue MC903 is effective in the treatment of 
psoriasis [13]. It is at least as effective as betamethasone with regard to the effect on 
epidermal growth. 
The reduction of 1^8.12 binding and DNA content showed a positive correlation 
with the reduction of the PASI-scores. (p < 0.006 and ρ < 0.03, respectively). As has 
been illustrated in table 1 the different stages of clinical improvement correspond well 
with the reduction of both parameters for epidermal growth. However, the values of 
these cell kinetic parameters were still increased above the normal range even in those 
patients who showed total clinical clearance. These findings have also been observed 
following treatment over 6 weeks with dithranol [14]. Therefore, these parameters for 
epidermal growth revealed pathological involvement beyond the discrimination level of 
clinical observation. 
The increased values of cell kinetic parameters at the end of antipsoriatic treatment 
despite clinical clearing are intriguing. Theoretically speaking, it is possible that these 
parameters normalize later on as a second order process after discontinuation of 
treatment. However, both topical steroids and MC903 have a direct antiproliferative 
effect as has been shown by in vitro studies [1,4,15,16]. An alternative explanation from 
a cell kinetic point of view is an incomplete treatment. In this respect we cannot 
exclude the possibility that MC 903 and betamethasone only apparently normalize the 
epidermis, leaving the basic defects in psoriasis unchanged. In the posttreatment follow-
up of the trial half of the patients showed a reappearance of new lesions within 4 
weeks. 
Whether further treatment after apparent clinical clearance might be associated with 
a prolonged remission period is uncertain. Continuation of treatment with PUVA or 
UVB following clinical resolution has resulted in extension of the remission period 
[17,18,19]. Further studies are indicated to determine whether maintenance treatment 
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with MC903 will result in complete normalization of the cellular kinetic parameters of 
the epidermis and longer penods of remission. 
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Chapter 7 
GENERAL DISCUSSION 

7 General Discussion 
7.1 METHODS 
Histopathology and immunohistochemistry are valuable tools for characterization and 
research of skin disorders [1]. Although the use of monoclonal antibodies is a mainstay 
in modern histopathology, it is important to realize certain limitations. For the 
monoclonal antibodies applied in this thesis their limitations will be briefly summarized: 
КІ67: In lymphocytes this monoclonal antibody has been proven to be a marker for 
actively cycling cells [2]. However, as stated in the introduction, its specificity in the 
epidermis has not yet entirely been established. The present thesis provides more 
evidence that: 
(i) nuclear staining of КІ67 can been observed exclusively in the basal cell layer 
(chapter 2 and 4.2). 
(¡i) all cells labelled with BrdUrd (S-phase cells) were positive to КІ67 as well 
(chapter 2). 
This antibody shows two different staining patterns: a cytoplasmatic and a nuclear 
binding [3]. In the assessment of the number of actively cycling cells exclusively the 
nuclear staining pattern is of relevance. Therefore flow cytometric quantification can be 
performed only on nuclei devoided from their cytoplasm. 
Ks8.12: This antibody has been described as specific for keratin 13 and keratin 16 [4]. 
Using gel-electrophoresis keratin 13 has never been shown in normal and psoriatic skin 
[5], whereas keratin 16 expression is restricted to hyperproliferative skin [6,7]. A 
remarkable finding is the focal staining pattern in the deeper rete-ridges of normal 
epidermis, approaching 3% of all epidermal cells (chapter 2, 4). The identity of this 
basal staining has not been clarified, however focal expression of keratin 16 or cross 
reactivity with keratin 15 are possible explanations. Using a monospecific antibody 
against keratin 13, this keratin was excluded to be responsible for this staining pattern 
[8, de Mare unpublished data]. 
Although the identification of the basal staining of keratin 16 would be in line with 
the supposition of relative hyperproliferative stem cells in the deeper rete-ridges [9], the 
persistence of this focal pattern following sellotape stripping is difficult to reconcile with 
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this thought. The interindividual variance of this staining pattern is compatible with the 
variable expression reported for keratin 15 [10]. 
Anli-BrdUrd: The specificity of this antibody is well established. The limitation is 
determined by the incorporation of its antigen BrdUrd and the accessibility of this 
antigen. However, the technique has been improved [11] yielding similar results as 
obtained with [3H]thymidine-labelling [12]. 
Despite these limitations these monoclonal antibodies were very useful in the context of 
this thesis, because of the wide range between the staining patterns of normal and 
psoriatic epidermis [4,12,13]. Especially in the evaluation of therapy it proved to give 
additional information as even clinically cleared epidermis showed elevated values of 
Ks8.12 binding and DNA-content. 
7.2 MECHANISMS OF HYPERPROLIFERATION 
Hyperproliferation of the epidermis is an important feature of psoriasis [14]. Therefore 
the mechanisms of its control is one of our major fields of interest. In order to define 
the area of future research it is of relevance whether hyperproliferation is a reflection 
of an increased growth-fraction (G0-hypothesis) [15] or a shortening of the cell cycle 
[16]. In chapter 2 it is shown that the ratio between cells in S-phase and cycling cells is 
constant, which implies a constant duration of the cell cycle. A further support for the 
G0 hypothesis is provided by the increased number of Ki67+ cells in the psoriatic lesion, 
reflecting an increased recruitment of cycling cells. To a lesser extent this increased 
recruitment is observed in atopic dermatitis, which indicates that this mechanism of 
hyperproliferation is not specific for psoriasis. 
This phenomenon of recruitment can be initiated reproducibly by standardized 
trauma, which proves that it is rather a "physiological" phenomenon of regeneration and 
not confined to diseased skin. In this respect it is attractive to hypothesize that psoriasis 
is a result of a defective control of this "physiological" phenomenon. Clinically, leads for 
this lapsed woundhealing are the Köbner response [17] and the preferential localization 
of psoriasis at sites frequently exposed to microtraumata [18]. 
An intriguing, but well established aspect of the cutaneous response to sellotape 
stripping, is the long delay between the trauma and the recruitment of cycling cells 
[chapter 4.1,19]. The interpretation of this aspect in molecular terms only can be 
speculative so far. Probably various devices of the wound healing process are 
implicated: 
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(i) Signal transducing pathway [20,21]. 
(ii) Transcription of gene regulatory proteins [22]. 
(iii) Attachment and de-attachment of the cell to extracellular matrix molecules 
[22]. 
(iv) Inflammation as an intermediary step [23,24]. 
Although hyperproliferation is obviously restricted to the basal cell compartment, the 
regulation of epidermal growth involves both compartments neighbouring the 
germinative cell pool. Attachment to extracellular matrix molecules and inflammation 
constitute dermal processes. The relevance of the suprabasal compartment is illustrated 
by the following findings: 
(i) Occlusion following sellotape stripping prohibits the hyperproliferative 
response [25]. 
(ii) Several components of the signal transducing pathways and proto-oncogenes 
have been demonstrated in the suprabasal compartment [26]. 
73 RELATION BETWEEN KERATINIZATION AND PROLIFERATION 
It is generally believed that the expression of keratin 16 is associated with 
hyperproliferation of the epidermis [6,7]. As a marker for hyperproliferation the 
immunohistochemical detection of keratin 16 using the monoclonal antibody Ks8.12 is 
of interest for psoriasis research [4]. Indeed, in chapter 3 a pronounced difference 
between normal and lesionai epidermis could be shown. In the general introduction it 
has been mentioned that it is not a psoriasis-specific phenomenon as it is found in 
malignant and benign hyperproliferation as well. Although these studies suggest that 
keratin 16 is hyperproliferation-associated, investigations on the interphase between 
normal and hyperproliferative skin may throw some light on the question whether this 
change in keratinization precedes or is secondary to hyperproliferation. 
7_3.1 Sequence of proliferation and keratinization 
In the margin of the spreading psoriatic plaque and in pinpoint papules (chapter 4.2) 
the suprabasal staining of Ks8.12 proved to appear peripherally to the transition point 
of КІ67, representing the recruitment of cycling cells. More centrally in the lesion 
virtually negative areas with respect to RKSE60 staining were seen. As described in 
chapter 4.2 the RKSE60 staining showed an inverse relation to the Ks8.12 staining. The 
margin zone is an adequate model for the topographic relationship between 
keratinization and proliferation and this can be interpreted in terms of a 'sequence of 
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events'. 
By monitoring the parameters of keratinization and proliferation after standardized 
trauma the sequence of events can be quantified on a time-table. As has been shown in 
chapter 4.1, Ks8.12 binding was significantly increased at 16 hours after stripping 
reaching a maximum at 24 h after stripping. Increased DNA synthesis was observed 
well after the changes in Ks8.12 binding (40 h after stripping). Again RKSE60 binding 
decreased after both events (48 h after stripping). 
From the topographical study in the margin zone it can be concluded that the 
induction of Ks8.12-binding appears in the utmost margin as an isolated event high in 
the suprabasal compartment without any connection with the basal cell layer. This 
observation is not compatible with the concept of abnormal keratinization as a result of 
hyperproliferation, but rather suggests a primary role of the suprabasal layer in 
epidermal growth control. The constant interval between changes of Ks8.12 and DNA 
synthesis found in the sellotape stripping model further supports this view. 
7.3.2 Mechanisms of suprabasal growth control 
In general two principles of growth control exist. On one hand a negative feed back 
system can inhibit proliferation in order to normalize it. On the other hand positive 
signals, such as growth factors, can induce hyperproliferation depending on their 
production and receptor binding. 
Bullough suggested the existence of chalones which specifically inhibit epidermal 
growth [27]. Various investigators have isolated fractions from epidermis with chalone-
like activity [28]. The removal of chalone-producing cells is a possible explanation for 
the induction of hyperproliferation in the wound healing process. During the past 
decade the research interest in chalones has diminished. Recently however, Wertz and 
Downing reported on considerable amounts of free sphingosine in human epidermis 
[29]. Sphingosine is a well-established inhibitor of protein kinase C, which is a pivotal 
enzyme in epidermal growth and keratinization [30]. Sphingosine is localized in the 
stratum corneum. Therefore, it is understandable that stripping off the stratum 
corneum results in hyperproliferation. A recent experiment of Proksch et al. [25] 
suggests that elimination of a negative stimulus can not be the whole explanation. The 
authors reported that plastic occlusion after sellotape stripping partially decreased the 
hyperproliferative response. 
Currently, research on epidermal proliferation and keratinization is focused on 
signal transducing pathways and related protein kinases. In vitro it has been shown that 
protein kinase С stimulates both epidermal proliferation and keratinization [30,31,32]. 
The same holds true for the protein kinase С dependent enzyme ornithine 
decarboxylase (ODC) [33,34]. By immunohistochemical investigations it has been shown 
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that both enzymes are localized predominantly in the suprabasal compartment [26,35] 
In this respect it is of relevance that protein kinase С is down-regulated by 
overactivation in the clinically uninvolved skin of psoriatic patients [36]. ODC activity 
and its products (polyamines) are increased in the symptomless skin Following 
sellotape stripping protein kinase С dependent events, such as arachidonic acid release 
and ODC induction proved to be early events (within 8 h after injury) [20] Another 
stimulus for proliferation is TGFa, which is the hgand for the EGF-receptor Recently, 
increased levels of TGFa-RNA has been reported to occur exclusively in the suprabasal 
compartment [37] These literature data suggest that the suprabasdl compartment is of 
relevance for the induction of hyperproliferation. This is in line with our studies on in 
vivo models showing changes of Ks8.12 binding in the suprabasal compartment 
preceding the recruitment of cells in the basal compartment. 
7.4 ASPECTS OF ANTI-PSORIATIC THERAPY 
7.4.1 Dithranol 
Dithranol has proved to be an effective treatment without important side-effects in a 
clinical setting for over 75 years. The clinical setting made dithranol a therapy for 
patients with an extensive psoriasis, less affected patients had to be treated at the 
outpatient department with corticosteroids or photo(chemo)therapy, which may have 
serious long-term side-effects. 
The major problems with respect to the management of dithranol therapy on the 
outpatient department are staining and irritation [38] An approach to circumvent these 
problems is short contact therapy This scheme is based on penetration studies showing 
an marked bioavailability of dithranol in the lesionai skin with minimal penetration of 
the uninvolved skin if the application period is one hour or less [39,40] 
The efficacy of short contact dithranol therapy on an outpatient basis was proven by 
the treatment of a patient with ILVEN and superimposed psoriasis (chapter 5 2) 
Dithranol cleared nearly all lesions and released the patient of an unbearable itch In 
the past this linear psoriasis had been resistant against all the other anti-psonatic 
therapies (corticosteroid, UVB and PUVA). 
The frequency of concentration adjustments and intensified guidance of the patients 
proved to be significant factors to improve the short contact therapy (chapter 5 1) At a 
general outpatient department the prerequisites for frequent time-consuming visits are 
mostly insufficient Therefore organization of special consultation hours or alternatively 
a day-care centre seem to be more appropriate. 
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The development of vehicles for short-contact therapy should encompass with two 
objectives: 
(i) bioavailability 
(ii) removability 
With respect to the first objective a greasy base is advantageous [38]. A new 
preparation, Psoralon" (Hermal, Hamburg, FRG) is a successful compromise (chapter 
5.3). This preparation is fatty and contains detergents, which guarantees easy removal 
and minimal posttreatment staining. The classical approach to increase stability and 
penetration of dithranol into the epidermis is the addition of salicylic acid. This addition 
has proved to be of no value in Psoralon" (chapter 5.3). 
7.4.2 Vitamin Ό3 
The discovery of receptors for vitamin D3 in the epidermis leads one to suspect that the 
epidermis is not only an organ for its metabolism, but a target as well. The effects of 
vitamin Од were found in several in vitro studies and includes inhibition of proliferation, 
stimulation of differentiation, immunomodulation and interference with the calcium 
metabolism. It is not known which mechanism is important for the anti-psoriatic effect 
which was found later. 
Most clinical studies done so far with calcitriol were open studies, which did not 
permit a definitive statement about the anti-psoriatic efficacy. Using a double blind 
approach we could not demonstrate any clinical efficacy of calcitriol [41]. This was 
confirmed quantitatively by use of the sellotape stripping model. No inhibition of 
recruitment of cycling cells could be detected after calcitriol treatment (chapter 6.1). 
The most likely explanation is insufficient bioavailability. Higher dosages, however were 
hazardous in view of interference with systemic calcium homoeostasis. 
Recently, the vitamin Da-analogue MC903 became available for clinical trial, which 
has a more favourable benefit-risk ratio [42,43]. As has been described in chapter 6.2 
topical treatment with MC903 was comparable with a medium strength corticosteroid in 
terms of clinical efficacy. In view of the low toxicity-potential MC903 is a promising 
therapy for psoriasis. 
7.43 Cell biological aspects 
During the three treatments studied for this thesis (dithranol, MC903 and 
betamethasone) the binding to monoclonal antibody Ks8.12 decreased. During the 
treatment with MC903 and betamethasone this also holds true for DNA synthesis. Both 
differentiation and proliferation improved simultaneously. During a six weeks treatment 
with dithranol the percentage of cells in SG2M-phases remained increased, although 
Ks8.12 binding decreased as seen during the other therapies. This discrepancy can be 
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explained by a direct effect of dithranol on D N A of cycling cells On the strength of 
this, the mechanism of MC903 and betamethasone to inhibit proliferation must be 
located earlier in the cell cycle (G,-phase) or even interfere with the recruitment of the 
G 0 cell population. For corticosteroids such an effect has been shown using the 
sellotape stripping model [44] For MC903 the antipsonatic working mechanism is still 
unknown, however multiple targets of this drug might be of relevance in this disorder 
Although most of the patients cleared during the treatments the cell biological 
parameters remained elevated The question anses whether these parameters reflect 
the clinical situation. Statistical analysis showed a high correlation between the 
percentages of Ks8 12 positive cells or cells in SG2M phases and clinical improvement 
in treatments with MC903 and betamethasone. Therefore these still elevated 
parameters are of relevance and might indicate a follow-up treatment in order to 
extend the remission period [45,46] 
In addition, the monitoring of cell biological parameters has another advantage in 
our study of 20 patients (chapter 6 2) the improvement of Ks812 binding was 
significantly better at the MC903 treated side as compared with the betamethasone 
treated side Clinically, this difference was absent in the study of twenty patients, but in 
the whole multi-centre study, comprising 345 patients, a difference was present [47] 
This parameter may therefore be of some value and might be of interest for the 
evaluation of other new anti-psonatic drugs 
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Summary 
In the introduction (chapter 1) first a few general aspects of psoriasis are mentioned: 
history, clinical aspects, histological aspects and pathogenesis. From the pathogenetic 
point of view this thesis is focused on differences between psoriatic and normal 
epidermis in keratinization and proliferation. Immunohistochemistry and flow cytometry 
are introduced as techniques to investigate these differences as well as the markers 
used for this purpose: K,8.12, КІ67, RKSE60 and BrdUrd. To study the dynamics and 
the relationship between proliferation and keratinisation in vivo models are used, e.g. 
the stripping-model, the margin zone-model and the therapeutical regression. 
Chapter 2 provides additional evidence for the G0 hypothesis. First, in comparison with 
normal epidermis the psoriatic epidermis shows a higher number of cycling cells (Ki67+ 
nuclei) establishing a difference in growth fraction between normal and psoriatic 
epidermis. Second, the ratio between cells in S-phase (BrdUrd* nuclei) and cycling cells 
(Ki67+ nuclei) is the same for normal and psoriatic epidermis. Knowing that the 
duration of the S-phase is 8-10 h in both situations, this constant ratio indicates a 
constant cell cycle time (26 h). 
In chapter 3 the induction of keratin 16 expression in hyperproliferative epidermis and 
psoriasis is visualized using the monoclonal antibody K,8.12. In contrast to the patchy 
basal staining in normal epidermis, 1^8.12 binds to the suprabasal compartment in the 
hyperproliferative epidermis. 
In chapter 4, two in vivo models are used to study the relation between changes in 
proliferation and keratinization. In both models induction of keratin 16 expression 
precedes the changes in proliferation markers. In the stripping model this relation is 
quantified in terms of time, showing a constant time-lag between the induction of 
keratin 16 and the recruitment of cycling cells. In the model of the margin zone of 
spreading plaque psoriasis the relation is observed topographically, showing an isolated 
K,8.12 binding in the suprabasal compartment. This localization suggests a role of the 
suprabasal compartment in proliferation control. 
Chapter 5 reports on the outpatient management of psoriasis with dithranol therapy. 
Intensive guidance improves the results of this therapy. The successful treatment of a 
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recalcitrant linear psonasis in a patient with ILVEN proves the therapeutical efficacy of 
the short contact schedule. In a clinical trial with dithranol (with and without the 
addition of salicylic acid) the influence of keratinization and proliferation was studied. 
Whilst keratin 16 expression decreased, the number of cycling cells remained elevated 
This dissociation is explained by the incorporation of dithranol in DNA synthesizing 
cells, resulting in a S0 phase. 
Chapter 6 discusses the development of a new anti-psonatic treatment: topical vitamin 
D3. The first analogue was tested in the sellotape stripping model, showing no 
interference with the recruitment of cycling cells after trauma. Second analogue was 
tested in a double blind clinical trial using an intra-individual left/right comparison 
between a middle strength corticosteroid and the vitamin Dj-analogue MC903. 
Clinically both treatments showed the same response. For the cell biological parameters 
there was a significant difference in keratin 16 reduction in favour of the vitamin D3 
treated site. A decrease of cycling cells was found after both treatments without any 
difference. 
In chapter 7 proliferation and keratinization and their relationship is discussed in the 
light of this thesis. The present thesis lends further support to the concept that an 
increased recruitment of cycling cells is the mechanism of psoriatic hyperprohferation. 
Keratinization in hyperproliferative epidermis is changed by expression of keratin 16 in 
the suprabasal compartment. The dynamics between abnormal keratinization and the 
recruitment process in the basal cell compartment suggests a crucial role of the 
suprabasal zone in the induction of psoriatic hyperprohferation. 
The efficacy of dithranol therapy on an outpatient basis and the favourable results 
of MC903 treatment justify some therapeutic optimism for patients with psoriasis A 
differential effect of these treatments on the process of epidermal growth and 
differentiation could be demonstrated. 
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Samenvatting 
Dit proefschrift gaat over proliferatie en keratìnisatie in psoriasis. Centraal staat de 
relatie tussen beide processen tijdens de inductie en regressie van de psoriasis laesie. 
In hoofdstuk 1, de introductie, komen allereerst enkele algemene facetten van psoriasis 
aan de orde: geschiedenis, klinische aspecten, histologische aspecten en Pathogenese. 
Vanuit de Pathogenese spitst de aandacht zich toe op het verschil tussen psoriasis en 
normale huid wat betreft de processen proliferatie en keratìnisatie. Immuunhistochemie 
en flow cytometrie worden geïntroduceerd als technieken om dit verschil te 
onderzoeken, evenals de markeerstoffen die daarbij gebruikt worden: KJ&.12, KÌ67, 
RKSE60 en BrdUrd. Om de dynamiek en de relatie tussen proliferatie en keratìnisatie 
te onderzoeken is gebruikt gemaakt van in vivo modellen, namelijk het strip model, het 
randzone model en het model van de therapeutische regressie. 
Hoofdstuk 2 gaat over proliferatie. Voor het bestaan van de zogenaamde G0-fase wordt 
aanvullend bewijs geleverd: ten eerste is een groter aantal cyclische cellen (Ki67+ 
nuclei) gevonden in de epidermis van een psoriasis laesie in vergelijking met de 
normale epidermis. Deze constatering bevestigt het verschil in groeifractie. Ten tweede 
is er tussen de epidermis van een psoriasis laesie en de normale epidermis geen verschil 
in de verhouding van cellen in S-fase (BrdUrd+ nuclei) en cyclische cellen (Ki67+ 
nuclei). Uitgaande van een gelijke duur van de S-fase in beide situaties (8-10 uur), 
impliceert deze constante verhouding een constante celcyclus tijd (26 uur). 
Hoofdstuk 3 gaat over keratìnisatie. Het verschil in keratìnisatie tussen psoriasis en 
normale epidermis wordt aangetoond met het monoclonale antilichaam Κ,8.12. Dit 
antilichaam richt zich o.a. tegen kératine 16, wat tot expressie komt in 
hyperproliferalieve epidermis, zoals in regeneratieve huid en psoriasis. In tegenstelling 
tot de pleksgewijze basale kleuring van K,8.12 in de normale epidermis bindt dit 
monoclonale antilichaam de suprabasale laag in de hyperproliferalieve epidermis. 
Hoofdstuk 4 gaat over de relatie tussen proliferatie en keratìnisatie. De veranderingen 
in deze processen zijn tegelijkertijd onderzocht in twee ш vivo modellen. In beide 
modellen gaat de inductie van kératine 16 vooraf aan de verandering in proliferatie. In 
het strip-model is deze relatie gekwantificeerd door een constant tijdsinterval tussen het 
ontstaan van kératine 16-expressie en de toename in DNA synthese. In het randzone-
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model van de groeiende psoriasis laesie is deze relatie topografisch onderzocht. Er is 
een geïsoleerde suprabasale binding van K,8.12 gevonden. Deze lokalisatie kan wijzen 
op een rol voor dit compartiment in de controle van proliferatie. 
Hoofdstuk 5 gaat over het effect van de klassieke behandeling van psoriasis patiënten 
met dithranol, op proliferatie en keratinisatie. Deze behandeling werd gemodificeerd 
voor poliklinisch gebruik. Het blijkt dat het resultaat verbetert door een intensieve 
begeleiding. De succesvolle behandeling van een therapie-resistente lineaire psoriasis bij 
een patiënt met IL VEN bewijst het therapeutische effect van het 'korte contact' 
schema. In een klinische trial met dithranol (met en zonder toevoeging van salicylzuur) 
werd de invloed van de therapie op keratinisatie en proliferatie vastgesteld. Terwijl de 
kératine 16 expressie vermindert, blijft het aantal cyclische cellen verhoogd. Deze 
discrepantie is te verklaren door de opname van dithranol in DNA synthetiserende 
cellen, waardoor een S0 fase ontstaat. 
Hoofdstuk 6 gaat over het effect van een nieuwe therapie, lokale vitamine D3, op 
proliferatie en keratinisatie. Het eerste analoog werd getest met het strip-model. Er is 
geen interferentie gevonden met de recrutering van cyclische cellen na standaard 
trauma. Het tweede analoog werd getest in een dubbelblinde trial met een intra-
individuele rechts/links vergelijking tussen een klasse 3-corticosteroïd en het vitamine 
Dj-analoog MC903. Klinisch is er geen verschil tussen de beide therapieën. In de 
celbiologische parameters is wel een significant verschil gevonden in de afname van 
kératine 16-expressie in het voordeel van vitamine D3. Na toepassing van beide 
therapieën was de afname van het aantal cyclische cellen gelijk. 
Hoofdstuk 7 gaat over proliferatie en keratinisatie en hun onderlinge relatie, in het licht 
van de resultaten uit dit onderzoek. Dit proefschrift ondersteunt de hypothese dat het 
mechanisme van de hyperproliferatie bij psoriasis is gebaseerd op een toegenomen 
recrutering van cyclische cellen. De keratinisatie in hyperproliferatieve huid is duidelijk 
anders dan in normale huid door de expressie van kératine 16 in het suprabasalc 
compartiment. De relatie tussen abnormale keratinisatie en het recruterings-proces in 
het basale compartiment suggereert een cruciale rol van de suprabasale zone bij de 
inductie van hyperproliferatie in de psoriasis laesie. 
De effectiviteit van de poliklinische dithranoltherapie en de veelbelovende resultaten 
van de MC903 behandeling rechtvaardigt een therapeutisch optimisme voor de 
behandeling van patiënten met psoriasis. Een verschillend effect van deze 
behandelingen op de processen van epidermale groei en differentiatie kon worden 
aangetoond. 
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